MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Cancer Chemotherapy and Pharmacology' source. Fri, 19 Mar 2010 13:57:19 +0100 http://www.medworm.com/index.php?rid=3375456&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh116521887270520%2F Conclusion  This sequential treatment is feasible with a favourable safety profile and produced encouraging results in terms of activity and efficacy. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1196-1Authors Fotios Loupakis, University of Pisa Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori and Department of Oncology, Transplants and New Technologies in Medicine Via Roma, 67 56126 Pisa ItalyGianluca Masi, University of Pisa Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori and Department of Oncology, Transplants and New Technologies in Medicine Via Roma, 67 56126 Pisa ItalyLorenzo Fornaro, University of Pisa Unit of Medical Oncology 2, Azienda Osp... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3375456 Tue, 16 Mar 2010 14:49:02 +0100 3375456 http://www.medworm.com/index.php?rid=3366959&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F867h3186t44pk381%2F Conclusions  AZD3409 inhibits farnesylation to a higher extent than geranylgeranylation. Both inhibition of farnesylation and geranylgeranylation could not be correlated to the antiproliferative activity of the drug. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1300-6Authors Natalie M. G. M. Appels, Slotervaart Hospital/The Netherlands Cancer Institute Department of Pharmacy & Pharmacology Louwesweg 6 1066 EC Amsterdam The NetherlandsMaria J. Bolijn, The Netherlands Cancer Institute/Antoni Van Leeuwenhoek Hospital Department of Medical Oncology Plesmanlaan 121 1066 CX Amsterdam The NetherlandsMaria A. J. van Eijndhoven, The Netherlands Cancer Institute/Antoni Van Leeuwenhoek Hospital Department of Medical Oncology Plesmanlaan 121 1066 CX... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3366959 Sun, 14 Mar 2010 11:29:32 +0100 3366959 http://www.medworm.com/index.php?rid=3360352&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx66k483u63335034%2F Conclusion  FOLFIRI regimen is effective and well tolerated in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin in Chinese population. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1301-5Authors Han Ying Bao, Zhejiang University Department of Medical Oncology, The First Affiliated Hospital, School of Medicine 79 Qingchun Rd. 310003 Hangzhou ChinaWei Jia Fang, Zhejiang University Department of Medical Oncology, The First Affiliated Hospital, School of Medicine 79 Qingchun Rd. 310003 Hangzhou ChinaXiao Chen Zhang, Zhejiang University Department of Medical Oncology, The First Affiliated Hospital, School of Medicine 79 Qingchun Rd. 310003 Hangzhou ChinaGen Ming Shi, Zhejiang University Department of Medi... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3360352 Thu, 11 Mar 2010 07:57:21 +0100 3360352 http://www.medworm.com/index.php?rid=3360351&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7q226m48054520kx%2F Conclusions  Clinical trials may be feasible in second- or third-line salvage chemotherapy for gastric cancer. Future clinical trials in these settings should take into account the low response rate, short progression-free survival, and the prognostic factors for optimal trial design. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1295-zAuthors Yong Wha Moon, Yonsei University College of Medicine Cancer Metastasis Research Center 250 Seongsanno Seodaemun-gu, Seoul 120-752 KoreaSun Young Rha, Yonsei University College of Medicine Cancer Metastasis Research Center 250 Seongsanno Seodaemun-gu, Seoul 120-752 KoreaHei-Cheul Jeung, Yonsei University College of Medicine Cancer Metastasis Research Center 250 Seongsanno Seodaemun-gu, Seoul 120-752... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3360351 Thu, 11 Mar 2010 07:57:21 +0100 3360351 http://www.medworm.com/index.php?rid=3360353&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm12031g56k184625%2F Conclusion  Vorinostat has the capacity to elicit CRT exposure, suggesting its usefulness as immunogenic antitumour agent. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s00280-010-1302-4Authors Jürgen Sonnemann, University Children’s Hospital Jena Department of Paediatric Haematology and Oncology Jena GermanyStephanie Greßmann, University Children’s Hospital Jena Department of Paediatric Haematology and Oncology Jena GermanySabine Becker, University Children’s Hospital Jena Department of Paediatric Haematology and Oncology Jena GermanySusan Wittig, University Children’s Hospital Jena Department of Paediatric Haematology and Oncology Jena GermanyMareike Schmudde, Ernst Moritz Arndt University Institute for Immunology and Transfusion Medicin... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3360353 Thu, 11 Mar 2010 02:38:49 +0100 3360353 http://www.medworm.com/index.php?rid=3360355&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F485m23175l26858x%2F Conclusion  Patients with isolated PAN metastasis showed an excellent prognosis compared with patients with metastasis at other sites and it was primarily evident in patients with recurrent PAN metastasis. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1296-yAuthors In Hae Park, National Cancer Center Center For Gastric Cancer, Research Institute and Hospital 323 Ilsan-Ro, Ilsandong-Gu Goyang Gyeonggi 410-769 Republic of KoreaSun Young Kim, National Cancer Center Center For Gastric Cancer, Research Institute and Hospital 323 Ilsan-Ro, Ilsandong-Gu Goyang Gyeonggi 410-769 Republic of KoreaYoung-Woo Kim, National Cancer Center Center For Gastric Cancer, Research Institute and Hospital 323 Ilsan-Ro, Ilsandong-Gu Goyang Gyeonggi 410-769 Republ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3360355 Thu, 11 Mar 2010 02:38:47 +0100 3360355 http://www.medworm.com/index.php?rid=3360354&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl8n855426747705u%2F Conclusion  The vinorelbine plus gemcitabine combination at the present doses and schedule is a safe but ineffective regimen, and therefore, is not recommended as second-line and beyond treatment in patients with refractory ovarian cancer. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1284-2Authors N. Xenidis, University General Hospital of Alexandroupolis Department of Medical Oncology Dragana 68100 Alexandroupolis, Thrace GreeceK. Neanidis, University General Hospital of Alexandroupolis Department of Medical Oncology Dragana 68100 Alexandroupolis, Thrace GreeceK. Amarantidis, University General Hospital of Alexandroupolis Department of Medical Oncology Dragana 68100 Alexandroupolis, Thrace GreeceP. Dimopoulos, University General Hospita... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3360354 Thu, 11 Mar 2010 02:38:47 +0100 3360354 http://www.medworm.com/index.php?rid=3355564&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1767g56p03120251%2F Abstract  The anti-diabetic thiazolidinedione compound pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, and selective cyclooxygenase-2 inhibitors are clinically used in patients with advanced malignancies. Several previously published in vivo and in vitro studies showed growth inhibitory effects on different cancer cell lines. However, the underlying mechanisms are fairly unclear. Here, we analyzed the effects of pioglitazone in combination with other drugs in a three-dimensional multicellular tumor spheroid culture system (MCTS) generated from the two prostate carcinoma cell lines PC3 and LNCaP. As expected, pioglitazone also inhibited tumor cell proliferation in the MCTS system. Further studies revealed that pioglitazone lowered the pH of the cult... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3355564 Wed, 10 Mar 2010 15:56:08 +0100 3355564 http://www.medworm.com/index.php?rid=3355566&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F067221p377731682%2F Conclusions  Oral panobinostat with and without docetaxel is feasible, and docetaxel had no apparent effect on the pharmacokinetics of panobinostat. Since preclinical studies suggest a dose-dependent effect of panobinostat on PSA expression, and other phase I data demonstrate that intravenous panobinostat produces higher peak concentrations (>20- to 30-fold) and area under the curve (3.5x–5x), a decision was made to focus the development of panobinostat on the intravenous formulation to treat CRPC. Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s00280-010-1289-xAuthors Dana Rathkopf, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center Genitourinary Oncology Service, Department of Medicine 1275 Yo... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3355566 Wed, 10 Mar 2010 15:56:07 +0100 3355566 http://www.medworm.com/index.php?rid=3355565&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F83716652n7543451%2F Abstract  Since the discovery of cis-platinum, many transition metal complexes have been synthesized and assayed for antineoplastic activity. In recent years, ruthenium-based molecules have emerged as promising antitumor and antimetastatic agents with potential uses in platinum-resistant tumors or as alternatives to platinum. Ruthenium compounds theoretically possess unique biochemical features allowing them to accumulate preferentially in neoplastic tissues and to convert to their active state only after entering tumor cells. Intriguingly, some ruthenium agents show significant activity against cancer metastases but have minimal effects on primary tumors. Two ruthenium-based drugs, NAMI-A and KP1019, have reached human clinical testing. This review will highlight the chemic... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3355565 Wed, 10 Mar 2010 15:56:07 +0100 3355565 http://www.medworm.com/index.php?rid=3355567&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp20n476n4p580p35%2F Conclusions  Intraperitoneally administered CPT-11 was feasible and tolerable. Further, phase II study of IP CPT-11 in gastric cancer patients with peritoneal seeding is warranted. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1272-6Authors Moon Ki Choi, Sungkyunkwan University School of Medicine Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center 50 Irwon-dong, Gangnam-gu Seoul 135-710 KoreaByung-Jin Ahn, Dongguk University Medical Science Research Center Seoul KoreaDong-Seok Yim, The Catholic University of Korea Department of Pharmacology, College of Medicine Seoul KoreaYoung Suk Park, Sungkyunkwan University School of Medicine Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center 50... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3355567 Wed, 10 Mar 2010 15:56:06 +0100 3355567 http://www.medworm.com/index.php?rid=3355568&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F74055827241x3v46%2F Conclusion  We propose that the copper-dependent cellular redox status is an important element in the cytotoxic action of ascorbic acid against cancer cells. It is well established that cellular copper levels are considerably elevated in various malignancies. Therefore, cancer cells may be more subject to electron transfer between copper and ascorbate to generate reactive oxygen species. In light of these observations and those in literature, in this paper we explain that the preferential cytotoxicity of ascorbic acid against cancer cells is the result of elevated copper levels in such cells. Further, this study identifies nuclear copper as a novel molecular target for cytotoxic action of ascorbic acid, which has implications for its chemotherapeutic properties against canc... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3355568 Wed, 10 Mar 2010 15:56:05 +0100 3355568 http://www.medworm.com/index.php?rid=3355570&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fmlp026713xj62j0r%2F Conclusions  Although non-randomized, this study strongly suggests that prospective determination of DPD status has an immediate clinical benefit by reducing the drug-induced toxicities incidence in patients treated with 5-FU, allowing an optimal administration of several courses in a row, while maintaining efficacy. Our preliminary results thus advocate for systematic DPD screening in patients eligible for treatment with fluoropyrimidine drugs in HNC. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1282-4Authors Chen Guang Yang, La Timone University Hospital Medical Oncology Unit 234 Rue St Pierre 13385 Marseille cedex 05 FranceJoseph Ciccolini, La Timone University Hospital Federation de Pharmacologie Medicale et Clinique Marseille Fran... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3355570 Wed, 10 Mar 2010 15:56:03 +0100 3355570 http://www.medworm.com/index.php?rid=3355569&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn2n6lu7px5t517k2%2F Conclusion  The addition of sorafenib to carboplatin/paclitaxel chemotherapy was not feasible within this neoadjuvant regimen in primary advanced ovarian cancer. Although the occurrence of serious adverse events might have emerged at random, a detrimental effect of preoperative study medication could not be denied. Further evaluations of sorafenib in ovarian cancer are warranted. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s00280-010-1276-2Authors Martin Pölcher, University Hospital of Bonn Department of Gynecology and Obstetrics, Center for Integrated Oncology, Bonn University Medical Center Sigmund-Freud-Str. 25 53105 Bonn GermanyMeike Eckhardt, University Hospital of Bonn Department of Gynecology and Obstetrics, Center for Integrated Oncol... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3355569 Wed, 10 Mar 2010 15:56:03 +0100 3355569 http://www.medworm.com/index.php?rid=3355572&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F56468181754524l1%2F In this study, we investigated the induction of apoptosis by ultrasound in the presence of the photochemically active gallium–porphyrin complex, 7,12-bis(1-decyloxyethyl)-Ga(III)-3,8,13,17-tetramethyl-porphyrin 2,18-dipropionyl diaspartic acid (ATX-70). HL-60 cells were exposed to ultrasound for up to 3 min in the presence and absence of ATX-70, and the induction of apoptosis was examined by analyzing cell morphology, DNA fragmentation, and caspase-3 activity. Cells treated with 80 μM ATX-70 and ultrasound clearly showed membrane blebbing and cell shrinkage, whereas significant morphologic changes were not observed in cells exposed to either ultrasound or ATX-70 alone. Also, DNA ladder formation and caspase-3 activation were observed in cells treated with both ultrasound... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3355572 Wed, 10 Mar 2010 15:56:02 +0100 3355572 http://www.medworm.com/index.php?rid=3355571&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd102rvp1640070n0%2F We present a patient with metastatic renal cell carcinoma manifested as bilateral pulmonary nodules who developed a bilateral spontaneous pneumothorax 3 weeks after initiation of sunitinib therapy. We believe that sunitinib therapy resulted in necrosis of multiple pleural-based pulmonary nodules with central cavernization and ultimately rupture with bronchopleural fistula formation. Based on this experience, we advise that practitioners exercise caution when prescribing anti-VEGFR therapy in patients with pleural-based pulmonary metastases and recognize that the efficacy and toxicity of these agents may be closely linked. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s00280-010-1291-3Authors Anilkumar Katta, Saint Louis University School of Medicine D... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3355571 Wed, 10 Mar 2010 15:56:02 +0100 3355571 http://www.medworm.com/index.php?rid=3355573&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Flq8262hjj4035l18%2F Conclusion  To our knowledge, this is the first study to examine relationships between LBM, liver mass/function and epirubicin PK and toxicity. This exploratory work investigates the notion of organs and tissues having distinctive contributions to the distribution and metabolism of antineoplastic drugs. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1288-yAuthors Carla M. M. Prado, University of Alberta Department of Oncology, Cross Cancer Institute 11560 University Avenue Edmonton AB T6G 1Z2 CanadaIsac S. F. Lima, University of Alberta Public Health Sciences Edmonton AB CanadaVickie E. Baracos, University of Alberta Department of Oncology, Cross Cancer Institute 11560 University Avenue Edmonton AB T6G 1Z2 CanadaRobert R. Bies, Indiana Un... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3355573 Wed, 10 Mar 2010 15:56:01 +0100 3355573 http://www.medworm.com/index.php?rid=3355574&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F444t7574wq22p234%2F Conclusions  Patients with colorectal cancer mount an immune response to influenza vaccination irrespective of their chemotherapy regimen or timing. However, concurrent responses to all three strains in the individual patient with colorectal cancer are uncommon. The investigation of a booster vaccine in this population is warranted. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1292-2Authors Ajithkumar Puthillath, Roswell Park Cancer Institute Department of Medicine Elm and Carlton Buffalo NY 14221 USADonald L. Trump, Roswell Park Cancer Institute Department of Medicine Elm and Carlton Buffalo NY 14221 USAChris Andrews, University at Buffalo Department of Biostatistics Buffalo NY 14214 USAArvinder Bir, Roswell Park Cancer Institute Depar... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3355574 Wed, 10 Mar 2010 15:56:00 +0100 3355574 http://www.medworm.com/index.php?rid=3355576&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F37pg111q48787383%2F Conclusion  The MTD was HAI cisplatin 100 mg/m2 and systemic doxil 35 mg/m2. This regimen demonstrated antitumor activity, especially in breast cancer. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1266-4Authors Apostolia M. Tsimberidou, The University of Texas M. D. Anderson Cancer Center Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455 1515 Holcombe Boulevard Houston TX 77030 USAStacy Moulder, The University of Texas M. D. Anderson Cancer Center Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455 1515 Holcombe Boulevard Houston TX 77030 USASiqing Fu, The University of Texas M. D. Anderson Cancer Center Phase I Program, Department of Investigational Cancer Therapeutics, Unit 4... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3355576 Wed, 10 Mar 2010 15:55:58 +0100 3355576 http://www.medworm.com/index.php?rid=3355575&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb42j1540755728pm%2F Conclusions  A sequential strategy with TCF-dd followed by COFFI is very active and may be of special interest in selected patients. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1281-5Authors Matteo Dalla Chiesa, Azienda Ospedaliera di Cremona Departments of Medical Oncology and Biostatistics Cremona ItalyGianluca Tomasello, Azienda Ospedaliera di Cremona Departments of Medical Oncology and Biostatistics Cremona ItalySebastiano Buti, Azienda Ospedaliera di Cremona Departments of Medical Oncology and Biostatistics Cremona ItalyRodrigo Kraft Rovere, Azienda Ospedaliera di Cremona Departments of Medical Oncology and Biostatistics Cremona ItalyMatteo Brighenti, Azienda Ospedaliera di Cremona Departments of Medical Oncology and Biostatistics Cre... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3355575 Wed, 10 Mar 2010 15:55:58 +0100 3355575 http://www.medworm.com/index.php?rid=3336423&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft8p1x762175801t1%2F Conclusions  Induction IC followed by IC/RT showed poor efficacy and significant toxicity in patients with unresectable GC/EGJC. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1285-1Authors Fernando Rivera, H. U. Marqués de Valdecilla Medical Oncology Department Santander SpainMaica Galán, ICO L′Hospitalet Medical Oncology Department Barcelona SpainJosep Tabernero, Vall d’Hebron University Hospital Medical Oncology Department Barcelona SpainAndres Cervantes, University of Valencia Hematology and Medical Oncology Department, University Hospital Valencia SpainMª Eugenia Vega-Villegas, H. U. Marqués de Valdecilla Medical Oncology Department Santander SpainJavier Gallego, H. General U, Elche Medical Oncology Department Alicante SpainBerta... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3336423 Wed, 03 Mar 2010 08:50:08 +0100 3336423 http://www.medworm.com/index.php?rid=3312728&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fkh3576271520446q%2F Conclusion  In this series, metronomic etoposide was associated with significant clinical activity in STS. Further prospective investigations are necessary to identify those patients who are more likely to benefit from this strategy. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s00280-010-1275-3Authors Antoine Italiano, Institut Bergonié Department of Medical Oncology 229 cours de l’Argonne 33076 Bordeaux Cedex FranceMaud Toulmonde, Institut Bergonié Department of Medical Oncology 229 cours de l’Argonne 33076 Bordeaux Cedex FranceBarbara Lortal, Institut Bergonié Department of Pharmacy Bordeaux FranceEberhard Stoeckle, Institut Bergonié Department of Surgery Bordeaux FranceDelphine Garbay, Institut Bergonié Department of Medical Oncolog... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3312728 Thu, 25 Feb 2010 06:50:15 +0100 3312728 http://www.medworm.com/index.php?rid=3312729&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb88l48g684114376%2F Conclusions  For unselected chemotherapy-naïve Asian patients with NSCLC but ineligible for platinum doublets, empirical use of upfront erlotinib could not be recommended because of poor survival outcome. However, this can be given to selected subsets based on molecular or clinical predictors. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1280-6Authors Dae Ho Lee, University of Ulsan College of Medicine Department of Oncology Asan Medical Center, 388-1 Pungnap-2 dong, Songpa-gu Seoul 138-736 KoreaSang-We Kim, University of Ulsan College of Medicine Department of Oncology Asan Medical Center, 388-1 Pungnap-2 dong, Songpa-gu Seoul 138-736 KoreaCheolwon Suh, University of Ulsan College of Medicine Department of Oncology Asan Medical Center... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3312729 Thu, 25 Feb 2010 06:49:57 +0100 3312729 http://www.medworm.com/index.php?rid=3312730&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr23w1454g8747283%2F Conclusions  PNC-27 induces cancer cell membrane lysis by acting as the whole peptide, not fragments. The punctate yellow fluorescence is due to interaction of PNC-27 with intramembrane targets of MCF-7 cells that do not exist in the membrane of the untransformed cell line. This interaction increases the lifetime of PNC-27. Absence of these targets in the membranes of the untransformed MCF-10-2A cells results in initial uniform fluorescence of the double-labeled peptide in their membranes after which the peptide is degraded. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1166-7Authors Kelley A. Sookraj, SUNY Downstate Medical Center Department of Surgery 450 Clarkson Avenue Brooklyn NY 11203 USAWilbur B. Bowne, SUNY Downstate Medical Ce... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3312730 Thu, 25 Feb 2010 06:49:32 +0100 3312730 http://www.medworm.com/index.php?rid=3312731&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr47r58937nm25800%2F Conclusions  Both IFO and 4-OH-IFO can penetrate into the CSF of human adults without a correlation to CSF turnover. In contrast to IFO, 4-OH-IFO CSF penetration is not reliable with levels ranging between undetectable and exceeding those in the corresponding plasma. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1274-4Authors Philipp Kiewe, Charité Universitätsmedizin Berlin Department of Hematology, Oncology and Transfusion Medicine, Campus Benjamin Franklin Hindenburgdamm 30/31 12200 Berlin GermanyMartin Neumann, Charité Universitätsmedizin Berlin Department of Hematology, Oncology and Transfusion Medicine, Campus Benjamin Franklin Hindenburgdamm 30/31 12200 Berlin GermanyThomas Wagner, Universitätsklinikum Schleswig–Holstein, C... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3312731 Thu, 25 Feb 2010 06:49:31 +0100 3312731 http://www.medworm.com/index.php?rid=3308101&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F81172817hq50780l%2F Conclusions  IACC might cause hepatotoxicity that induces fibrosis without releasing aminotransferases. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1270-8Authors Hidenari Nagai, Toho University Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine 6-11-1, Omorinishi Ota-ku, Tokyo 143-8541 JapanTeppei Matsui, Toho University Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine 6-11-1, Omorinishi Ota-ku, Tokyo 143-8541 JapanMasahiro Kanayama, Toho University Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine 6-11-1, Omorinish... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3308101 Wed, 24 Feb 2010 06:47:47 +0100 3308101 http://www.medworm.com/index.php?rid=3303644&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu3n310j281362037%2F Conclusions  Overall, the data presented reveal that erufosine could have potential as an antimyeloma drug and deserves further development. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1273-5Authors Deyan Y. Yosifov, Medical University of Sofia Laboratory for Experimental Chemotherapy, Dept. of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy Dunav 2 1000 Sofia BulgariaPlamen T. Todorov, Bulgarian Academy of Sciences Institute of Biology and Immunology of Reproduction Tzarigradsko shosse 73 1113 Sofia BulgariaMaya M. Zaharieva, Medical University of Sofia Laboratory for Experimental Chemotherapy, Dept. of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy Dunav 2 1000 Sofia BulgariaKaloyan D. Georgiev, Toxic... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3303644 Tue, 23 Feb 2010 07:19:00 +0100 3303644 http://www.medworm.com/index.php?rid=3295542&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0wnt5366k2lh1r17%2F Conclusion  TTO combined with an effective carrier significantly inhibited the growth of aggressive, subcutaneous, chemo-resistant tumours in immunocompetent mice. Taken together, these findings highlight the potential of topical TTO as an alternative topical antitumour treatment. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1267-3Authors Sara J. Greay, The University of Western Australia Discipline of Microbiology and Immunology (M502), School of Biomedical, Biomolecular and Chemical Sciences 35 Stirling Highway Crawley WA 6009 AustraliaDemelza J. Ireland, The University of Western Australia Discipline of Microbiology and Immunology (M502), School of Biomedical, Biomolecular and Chemical Sciences 35 Stirling Highway Crawley WA 6009 Aus... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3295542 Sun, 21 Feb 2010 06:54:13 +0100 3295542 http://www.medworm.com/index.php?rid=3295543&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fxr205vj63436364n%2F Conclusions  Treatment with flavopiridol and FOLFIRI is a safe and effective regimen. Concentrations of flavopiridol that enhance the effects of FOLFIRI can be achieved. Clinical activity is encouraging and includes prolonged stable disease in patients with irinotecan-refractory colorectal cancer. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1269-1Authors Mark A. Dickson, Memorial Sloan-Kettering Cancer Center Melanoma and Sarcoma Service, Department of Medicine 1275 York Avenue New York NY 10065 USAManish A. Shah, Memorial Sloan-Kettering Cancer Center Gastrointestinal Oncology Service, Department of Medicine New York NY USADana Rathkopf, Memorial Sloan-Kettering Cancer Center Genitourinary Oncology Service New York NY USAArchie Tse, M... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3295543 Sun, 21 Feb 2010 06:54:12 +0100 3295543 http://www.medworm.com/index.php?rid=3295544&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fxx6x747666l7262l%2F Conclusion  Thus, sensitivity to cisplatin appeared to be associated with DDH levels in epithelial lung cancer cell lines with the DDH-1 isoform producing the greatest effect. Results in keeping with transfection experiments with ovarian and other cell lines. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1268-2Authors Jianli Chen, The Feinstein Institute for Medical Research North Shore-Long Island Jewish Health System 350 Community Drive Manhasset NY 11030 USANashwa Emara, Temple University School of Medicine Department of Pathology and Laboratory Medicine Philadelphia PA USACharalambos Solomides, Temple University School of Medicine Department of Pathology and Laboratory Medicine Philadelphia PA USAHemant Parekh, Temple University School... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3295544 Sun, 21 Feb 2010 06:54:11 +0100 3295544 http://www.medworm.com/index.php?rid=3295545&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fqt362j2h6324038k%2F Content Type Journal ArticleCategory EditorialDOI 10.1007/s00280-010-1271-7Authors Benjamin W. Corn, Tel Aviv Medical Center of Tel Aviv University School of Medicine Institute of Radiotherapy and Department of Oncology 6 Weizman Street Tel Aviv IsraelRavit Geva, Tel Aviv Medical Center of Tel Aviv University School of Medicine Institute of Radiotherapy and Department of Oncology 6 Weizman Street Tel Aviv Israel Journal Cancer Chemotherapy and PharmacologyOnline ISSN 1432-0843Print ISSN 0344-5704 (Source: Cancer Chemotherapy and Pharmacology) Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3295545 Sat, 20 Feb 2010 06:49:02 +0100 3295545 http://www.medworm.com/index.php?rid=3289076&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc62nm14m254mwn80%2F Conclusion  We developed a population pharmacokinetic model of oral busulfan in Japanese adults. The final population model was implemented into the program excel, leading to an easy and proper therapeutic monitoring of oral BU by using small number of samples. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s00280-010-1263-7Authors Yasushi Takamatsu, Fukuoka University Division of Medical Oncology, Hematology and Infectious Disease, Department of Medicine Nanakuma 7-45-1 Jonan-ku, Fukuoka 814-0180 JapanNoriaki Sasaki, Fukuoka University Department of Medical Informatics and Research Unit, Faculty of Pharmaceutical Sciences Fukuoka JapanKentaro Ogata, Fukuoka University Hospital Department of Pharmacy Fukuoka JapanEiji Yukawa, Daiichi University La... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3289076 Thu, 18 Feb 2010 17:53:26 +0100 3289076 http://www.medworm.com/index.php?rid=3285109&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fdw45gq643531t206%2F Conclusion  Obatoclax mesylate administered at 14 mg/m2 IV on days 1 and 3 is safe and well tolerated when given in combination with topotecan 1.25 mg/m2 IV on days 1–5 of an every 3-week cycle. A phase II trial to assess the efficacy of this combination for patients with relapsed SCLC is currently accruing patients. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1265-5Authors Paul K. Paik, Memorial Sloan-Kettering Cancer Center Thoracic Oncology Service, Department of Medicine New York NY 10065 USACharles M. Rudin, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore MD USAAndrew Brown, Memorial Sloan-Kettering Cancer Center Thoracic Oncology Service, Department of Medicine New York NY 10065 USANaiyer A. Ri... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3285109 Wed, 17 Feb 2010 18:27:33 +0100 3285109 http://www.medworm.com/index.php?rid=3280945&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fhxm842876732200p%2F Conclusions  Although 5FU is not a substrate for hepatic drug metabolising CYP enzymes, it may interfere with the synthesis of CYP2C19. Decreased activity of a related enzyme, CYP2C9, following 5FU has been reported previously. Down regulation of CYP2C9 and CYP2C19 synthesis by 5FU therapies may explain the adverse effect of 5FU on the clinical disposition of warfarin and phenytoin. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s00280-010-1277-1Authors N. A. Helsby, The University of Auckland Faculty of Medical and Health Sciences Auckland New ZealandW. Y. Lo, The University of Auckland Faculty of Medical and Health Sciences Auckland New ZealandP. Thompson, Auckland District Health Board Auckland Regional Cancer and Blood Service Auckland New Ze... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3280945 Tue, 16 Feb 2010 18:05:33 +0100 3280945 http://www.medworm.com/index.php?rid=3277097&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F54m273928k06m541%2F Conclusions  S-1 is active and well tolerated for the treatment of cytokine-refractory metastatic RCC. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1262-8Authors Seiji Naito, Kyushu University Department of Urology, Graduate School of Medical Sciences Fukuoka JapanTaiji Tsukamoto, Sapporo Medical University School of Medicine Department of Urology Sapporo JapanMichiyuki Usami, Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Urology Osaka JapanHiroyuki Fujimoto, National Cancer Center Hospital Urology Division Tokyo JapanHideyuki Akaza, University of Tsukuba Department of Urology and Andrology, Graduate School of Comprehensive Human Science Tsukuba, Ibaraki Japan Journal Cancer Chemotherapy and PharmacologyOn... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3277097 Mon, 15 Feb 2010 17:58:54 +0100 3277097 http://www.medworm.com/index.php?rid=3273501&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fpkl57x74k37n7262%2F Conclusion  With resistance to current breast cancer chemotherapies on the rise, the development of novel therapeutic targets is of growing importance. Our results show that lipid analogs have therapeutic potential in treating chemo- and endocrine-resistant breast cancer. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s00280-009-1233-0Authors James W. Antoon, Tulane University School of Medicine Department of Pharmacology 1430 Tulane Avenue New Orleans LA 70112 USAJiawang Liu, Xavier University of Louisiana Department of Chemistry 1 Drexel Drive New Orleans LA 70125 USAAdharsh P. Ponnapakkam, Tulane University School of Medicine Department of Pharmacology 1430 Tulane Avenue New Orleans LA 70112 USAMatthew M. Gestaut, Tulane University School of Med... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3273501 Sun, 14 Feb 2010 06:55:00 +0100 3273501 http://www.medworm.com/index.php?rid=3273502&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8161004820563287%2F Conclusion  Hyper-alkalinization appears an efficient and reliable method to prevent the acute renal toxicity of HDMTX and allows its safe administration in the outpatient setting. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1259-3Authors Olivier Mir, Université Paris Descartes, Assistance Publique, Hôpitaux de Paris Department of Medical Oncology, Teaching Hospital Cochin 27, rue du faubourg Saint-Jacques 75014 Paris FranceStanislas Ropert, Université Paris Descartes, Assistance Publique, Hôpitaux de Paris Department of Medical Oncology, Teaching Hospital Cochin 27, rue du faubourg Saint-Jacques 75014 Paris FranceAntoine Babinet, Université Paris Descartes, Assistance Publique, Hôpitaux de Paris Department of Orthopaedic Surgery, T... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3273502 Sat, 13 Feb 2010 06:45:57 +0100 3273502 http://www.medworm.com/index.php?rid=3247894&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9rw6771q71020072%2F Conclusions  A substantially higher accumulation of metabolites in peripheral blood mononuclear cells was observed when the longer infusion time was employed, suggesting a pharmacological advantage for this treatment schedule. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s00280-010-1255-7Authors Orazio Caffo, Santa Chiara Hospital Medical Oncology Department Trento ItalyStefania Fallani, University of Florence Department of Pharmacology Florence ItalyElena Marangon, Istituto di Ricerche Farmacologiche “Mario Negri” Laboratory of Cancer Pharmacology, Department of Oncology Milan ItalyStefania Nobili, University of Florence Department of Pharmacology Florence ItalyMaria Iris Cassetta, University of Florence Department of Pharmacology Florence It... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3247894 Fri, 05 Feb 2010 17:53:02 +0100 3247894 http://www.medworm.com/index.php?rid=3247895&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1x371t34tu516184%2F Conclusions  The BSA-based dosing regimen for bendamustine achieved the targeted exposure and was associated with a high incidence of therapeutic response. Given the short t 1/2 and low concentrations of bendamustine observed by 12 h after dosing, the single-dose profile for bendamustine described by these analyses is expected to be representative of the multiple-dose profile. The occurrence of nausea was significantly related to bendamustine exposure, with the probability of nausea increasing as bendamustine C max increases. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1254-8Authors Joel S. Owen, Cognigen Corporation 395 South Youngs Road Buffalo NY 14221 USAMurad Melhem, Cognigen Corporation 395 South Youngs Road Buffalo NY 1422... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3247895 Fri, 05 Feb 2010 17:53:01 +0100 3247895 http://www.medworm.com/index.php?rid=3240881&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq3r40k344751232t%2F Abstract  The optimal adjuvant treatment for gastric cancer remains controversial. We compared the efficacy of a docetaxel and platinum adjuvant chemotherapy regimen, in patients with high-risk gastric cancer, with that of the same chemotherapy plus radiation therapy (RT). In addition, we evaluated the prognostic and/or predictive value of a panel of molecular markers. Patients with histologically proven, radically resected gastric cancer, stage ≥T3 and/or N+ were randomized to 6 cycles of docetaxel with cisplatin, both at 75 mg/m2 every 3 weeks (arm A) or the same treatment with RT (arm B; 45 Gy). Due to excessive nausea and vomiting, cisplatin was substituted by carboplatin at AUC (area under the curve) of 5 after the first 45 patients (22 group ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3240881 Wed, 03 Feb 2010 17:55:10 +0100 3240881 http://www.medworm.com/index.php?rid=3240882&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8w5t455372768xv4%2F Conclusions  The combination of bevacizumab and erlotinib is safe but relatively ineffective in patients with gemcitabine-refractory metastatic pancreatic cancer. Future studies should focus on refining subsets of patients in this challenging population likely to benefit from treatment beyond first-line. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1257-5Authors Andrew H. Ko, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center 1600 Divisadero Street, 4th Floor Box 1705 San Francisco CA 94115 USAAlan P. Venook, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center 1600 Divisadero Street, 4th Floor Box 1705 San Francisco CA 94115 USAEmily K. Bergsland, University of C... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3240882 Wed, 03 Feb 2010 17:55:09 +0100 3240882 http://www.medworm.com/index.php?rid=3240883&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp144x63570230t27%2F Conclusions  This novel regimen of carboplatin with weekly docetaxel and ifosfamide has a favorable toxicity profile and is active in this setting. Phase II study results are awaited. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1251-yAuthors Ritesh Rathore, Roger Williams Hospital Division of Hematology/Oncology 825 Chalkstone Avenue Providence RI 02908 USAAriel Birnbaum, Rhode Island Hospital Division of Hematology/Oncology Providence RI USABharti Rathore, Roger Williams Hospital Division of Hematology/Oncology 825 Chalkstone Avenue Providence RI 02908 USAThomas DiPetrillo, Rhode Island Hospital Department of Radiation Oncology Providence RI USATeresa Kennedy, Brown University Oncology Group Providence RI USANeal Ready, Duke Medical Cent... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3240883 Wed, 03 Feb 2010 17:55:08 +0100 3240883 http://www.medworm.com/index.php?rid=3240884&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7771m1864r7j2761%2F Conclusion  Pemetrexed does not appear to have significant antitumor activity in patients with advanced neuroendocrine tumors. The limited antitumor activity and potential toxicity associated with pemetrexed mirrors experience with the majority of other cytotoxic agents in patients with neuroendocrine tumors. Investigation of novel, molecularly targeted agents may offer more promise in this disease. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1248-6Authors Jennifer A. Chan, Dana-Farber Cancer Institute Department of Medical Oncology Dana 1220, 44 Binney Street Boston MA 02115 USAAndrew X. Zhu, Massachusetts General Hospital Division of Hematology/Oncology Boston MA USAKeith Stuart, Beth Israel Deaconess Medical Center Division of Hemato... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3240884 Wed, 03 Feb 2010 17:55:07 +0100 3240884 http://www.medworm.com/index.php?rid=3232737&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl6h7177085122387%2F Conclusions  The MTD for this combination was 3-AP 60 mg/m2 per day on days 1–3 and irinotecan 200 mg/m2 on day 1 every 21 days. Antitumor activity in a patient with refractory non-small cell lung cancer was noted at level 1. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1250-zAuthors Brian S. Choi, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center 600 Highland Ave, K4/528 Madison WI 53792 USADona B. Alberti, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center 600 Highland Ave, K4/528 Madison WI 53792 USAWilliam R. Schelman, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center 600 Highland Ave, K4/528 Madison WI 53792 USAJill M. Kolesar, University of Wisconsin Paul P. Carbone... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3232737 Mon, 01 Feb 2010 18:02:15 +0100 3232737 http://www.medworm.com/index.php?rid=3228478&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9x7j725k6121lv43%2F Conclusions  Azacitidine is not an inhibitor or inducer of the cytochrome P450 isozymes tested; therefore, clinically relevant pharmacokinetic drug–drug interactions are unlikely to occur between azacitidine and co-administered substrates of these CYP isozymes. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s00280-010-1245-9Authors Yong Chen, Celgene Corporation Non-Clinical Development Summit NJ 07901 USALisa Liu, Celgene Corporation Non-Clinical Development Summit NJ 07901 USAEric Laille, Celgene Corporation Non-Clinical Development Summit NJ 07901 USAGondi Kumar, Celgene Corporation Non-Clinical Development Summit NJ 07901 USASekhar Surapaneni, Celgene Corporation Non-Clinical Development Summit NJ 07901 USA Journal Cancer Chemotherapy a... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3228478 Fri, 29 Jan 2010 17:57:54 +0100 3228478 http://www.medworm.com/index.php?rid=3228480&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fgg313n4p6243gw25%2F Conclusions  Rituximab may be indicated for early treatment of chemotherapy-induced TTP/HUS, particularly when plasma exchange is not rapidly effective. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s00280-010-1258-4Authors Brett L. Gourley, University of Minnesota Department of Medicine Minneapolis MN USAHector Mesa, VA Medical Center Department of Pathology Minneapolis MN USAPankaj Gupta, University of Minnesota Department of Medicine Minneapolis MN USA Journal Cancer Chemotherapy and PharmacologyOnline ISSN 1432-0843Print ISSN 0344-5704 (Source: Cancer Chemotherapy and Pharmacology) Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3228480 Fri, 29 Jan 2010 17:57:53 +0100 3228480 http://www.medworm.com/index.php?rid=3228479&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq138388613r13p40%2F Conclusions  These results indicate that, in MTX-treated rats, ZO-1 alterations may contribute to disturbance of the TJ barrier, which leads to enhanced intestinal permeability. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1253-9Authors Kazuma Hamada, Chiba University Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences 1-8-1 Inohana Chuo-ku Chiba 260-8675 JapanYoshihisa Shitara, Chiba University Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences 1-8-1 Inohana Chuo-ku Chiba 260-8675 JapanShuichi Sekine, Chiba University Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences 1-8-1 Inohana Chuo-ku Chiba 260-8675 JapanToshiharu Horie, Chiba University Department of Biopharmaceu... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3228479 Fri, 29 Jan 2010 17:57:53 +0100 3228479 http://www.medworm.com/index.php?rid=3223938&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw3663334506j12h1%2F Conclusions  Non-cytotoxic suramin, in combination with docetaxel 56 mg/m2 or gemcitabine 1,250 mg/m2, was reasonably well-tolerated with a manageable toxicity profile. Target plasma concentrations were correctly predicted by our previously described dosing nomogram. The observed preliminary evidence of antitumor activity encourages evaluation of this strategy in efficacy trials. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1252-xAuthors Elaine T. Lam, The Ohio State University Department of Internal Medicine, Division of Hematology and Oncology Columbus OH USAJessie L.- S. Au, The Ohio State University College of Pharmacy Columbus OH USAGregory A. Otterson, The Ohio State University Department of Internal Medicine, Division of ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3223938 Wed, 27 Jan 2010 20:24:53 +0100 3223938 http://www.medworm.com/index.php?rid=3223939&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv246535173567275%2F Conclusions  Cosmomycin D induced time-dependent apoptosis in nucleotide excision repair-deficient fibroblasts. Despite similar apoptosis levels, cosmomycin D caused considerably lower levels of DNA damage compared to doxorubicin. This may be related to differences in structure between cosmomycin D and doxorubicin. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s00280-010-1244-xAuthors Helotonio Carvalho, Federal University of São Paulo Department of Biological Sciences Diadema Campus Diadema SP BrazilLeandro M. Garrido, University of São Paulo Department of Microbiology, Institute of Biomedical Sciences Av. Prof. Lineu Prestes, 1374, Ed. Biomédicas 2 05508-900 São Paulo SP BrazilRenata L. A. Furlan, University of São Paulo Department of Micro... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3223939 Wed, 27 Jan 2010 20:24:50 +0100 3223939 http://www.medworm.com/index.php?rid=3223940&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc8832r2mwt4t51kg%2F Conclusions  The results of this study demonstrate that motesanib is tolerable in Japanese patients at doses up to 125 mg QD. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1243-yAuthors Yasuhito Fujisaka, National Cancer Center Hospital Division of Internal Medicine 5-1-1, Tsukiji Chuo-Ku Tokyo 104-0045 JapanYasuhide Yamada, National Cancer Center Hospital Division of Internal Medicine 5-1-1, Tsukiji Chuo-Ku Tokyo 104-0045 JapanNoboru Yamamoto, National Cancer Center Hospital Division of Internal Medicine 5-1-1, Tsukiji Chuo-Ku Tokyo 104-0045 JapanToshio Shimizu, National Cancer Center Hospital Division of Internal Medicine 5-1-1, Tsukiji Chuo-Ku Tokyo 104-0045 JapanYutaka Fujiwara, National Cancer Center Hospital Division of Internal M... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3223940 Wed, 27 Jan 2010 20:24:49 +0100 3223940 http://www.medworm.com/index.php?rid=3223942&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk20657129414m76r%2F Conclusions  It is important that physicians closely monitor anticoagulant activity in patients concomitantly receiving doxifluridine and warfarin, and appropriately adjust the dose of warfarin. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1249-5Authors Masaru Nakajima, Iida Municipal Hospital 438 Yawata-machi, Iida-shi Nagano 395-8502 JapanTomoo Genda, Iida Municipal Hospital 438 Yawata-machi, Iida-shi Nagano 395-8502 JapanMayu Suehira, Drug Lifetime Management Center 7-3-1 Hongo, Bunkyo-ku Tokyo 113-0033 JapanHiroki Satoh, The University of Tokyo Laboratory of Drug Informatics, Graduate School of Pharmaceutical Sciences 7-3-1 Hongo, Bunkyo-ku Tokyo 113-0033 JapanAkiko Miki, The University of Tokyo Laboratory of Drug Informatics, Graduate... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3223942 Wed, 27 Jan 2010 20:24:48 +0100 3223942 http://www.medworm.com/index.php?rid=3223941&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu6v1315521703n03%2F Conclusions  The recommended phase II doses are: tamoxifen 100 mg po bid, topotecan 0.75 mg/m2/d IV continuous infusion for 72 h, followed by carboplatin AUC = 3 IV on day 3. Measurable topotecan levels, both total and lactone, are observed in the CSF. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1242-zAuthors Robert J. Morgan, City of Hope Comprehensive Cancer Center Department of Medical Oncology and Therapeutics Research 1500 E. Duarte Rd. Duarte CA 91010 USATimothy Synold, City of Hope Comprehensive Cancer Center Department of Medical Oncology and Therapeutics Research 1500 E. Duarte Rd. Duarte CA 91010 USAAdam Mamelak, City of Hope Comprehensive Cancer Center Department of Neurosurgery Duarte CA 91010 USADean ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3223941 Wed, 27 Jan 2010 20:24:48 +0100 3223941 http://www.medworm.com/index.php?rid=3213671&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn637p762258j900j%2F Conclusion  The known activities of NSC109268 as proteasome or phosphatase inhibitor could explain the phenotype of S-phase delay by assuming a higher initial DNA damage load, inhibition of DNA translesion synthesis or extended checkpoint arrest. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1246-8Authors Dilip Jain, University of North Texas Health Science Center Department of Cell Biology and Anatomy 3500 Camp Bowie Blvd. Fort Worth TX 76107 USANila Patel, University of North Texas Health Science Center Department of Cell Biology and Anatomy 3500 Camp Bowie Blvd. Fort Worth TX 76107 USAMelanie Shelton, University of North Texas Health Science Center Department of Cell Biology and Anatomy 3500 Camp Bowie Blvd. Fort Worth TX 76107 USAAlakan... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3213671 Tue, 26 Jan 2010 07:02:54 +0100 3213671 http://www.medworm.com/index.php?rid=3205694&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy208v88x575qp661%2F Conclusions  Inhibition of the Bcl-2 family of proteins by ABT-263 enhances the cytotoxicity of multiple chemotherapeutics in hematologic tumors and represents a promising addition to the therapeutic arsenal for treatment of these diseases. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1232-1Authors Scott Ackler, Abbott Laboratories Global Pharmaceutical Research and Development Abbott Park IL USAMichael J. Mitten, Abbott Laboratories Global Pharmaceutical Research and Development Abbott Park IL USAKelly Foster, Abbott Laboratories Global Pharmaceutical Research and Development Abbott Park IL USAAnatol Oleksijew, Abbott Laboratories Global Pharmaceutical Research and Development Abbott Park IL USAMarion Refici, Abbott Laboratories Global Ph... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3205694 Sat, 23 Jan 2010 07:41:02 +0100 3205694 http://www.medworm.com/index.php?rid=3205695&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc1572t8710183380%2F Conclusions  Weekly schedule of docetaxel and cisplatin as first-line treatment for NSCLC had good efficacy and manageable toxicity. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1235-yAuthors Jung Hye Kwon, Hallym University Department of Internal Medicine, Kangdong Sacred Heart Hospital, College of Medicine 445 Gil-dong, Gangdong gu Seoul 134-701 South KoreaJung Han Kim, Hallym University Department of Internal Medicine, Kangnam Sacred Heart Hospital, College of Medicine 948-1, Daelim-1dong, Yeongdeugpo-gu Seoul 150-950 South KoreaJung-Ae Lee, Eulji University Hospital Department of Internal Medicine Seo-gu, Dunsan-dong 1306 Daejeon South KoreaHyun Chun Shin, Hallym University Department of Internal Medicine, Chuncheon Sacred Heart Hospita... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3205695 Fri, 22 Jan 2010 02:59:31 +0100 3205695 http://www.medworm.com/index.php?rid=3194918&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa5753780846v3l47%2F Conclusion  Phage-displayed peptide libraries can be a source of highly specific mimetopes for therapeutic mAb. The biotinylated forms of those peptides are compatible with conventional ELISA methods with sensitivities comparable to other assay methods and sufficient for pharmacological studies of those mAb given at high dose. The process outlined here can be applied to any mAb to enable improved pharmacokinetic analysis during the development and clinical use of this class of therapies. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1240-1Authors Ana B. Sanchez, University of California San Diego Moores Cancer Center 3855 Health Science Dr La Jolla CA 92093-0815 USATammy Nguyen, University of California San Diego Moores Cancer Center 3855... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3194918 Tue, 19 Jan 2010 17:39:31 +0100 3194918 http://www.medworm.com/index.php?rid=3190400&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj08607180v333246%2F Conclusion  High-dose fenretinide had limited anti-tumour activity in patients with advanced hormone refractory prostate cancer: further evaluation in this setting is not warranted. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1228-xAuthors M. M. Moore, Sydney Cancer Centre Hospital Rd Concord NSW 2139 AustraliaM. Stockler, University of Sydney Sydney Cancer Centre and NHMRC Clinical Trials Centre Missenden Rd Camperdown NSW 2050 AustraliaR. Lim, National University Hospital Department of Hematology-Oncology 5 Lower Kent Ridge Road Singapore 119074 Republic of SingaporeT. S. K. Mok, Prince of Wales Hospital Department of Clinical Oncology, Chinese University of Hong Kong Shatin Hong KongM. Millward, Sir Charles Gairdner Hospital Hospital A... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3190400 Fri, 15 Jan 2010 17:58:52 +0100 3190400 http://www.medworm.com/index.php?rid=3168486&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7108373717227626%2F Conclusions  The combination of S-1 and docetaxel is well tolerable and has substantial activity for patients with locally advanced or metastatic non-small cell lung cancer. A phase III trial comparing docetaxel with or without S-1 would warrant further investigation. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1239-7Authors Kazuhiro Yanagihara, Kyoto University Hospital Outpatient Oncology Unit Kyoto JapanKenichi Yoshimura, Kyoto University Hospital Department of Clinical Trial Design and Management, Translational Research Center Kyoto JapanMiyuki Niimi, Kyoto University Hospital Department of Clinical Trial Design and Management, Translational Research Center Kyoto JapanHiroyasu Yasuda, Kyoto University Hospital Outpatient Oncology Unit... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3168486 Tue, 12 Jan 2010 18:17:44 +0100 3168486 http://www.medworm.com/index.php?rid=3168487&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv3k821v60245n064%2F Conclusions  Our results show that HIF-1α is a critical target for MSC and its inhibition was associated with enhanced antitumor activity of irinotecan. Inhibition of HIF-1α appeared to be mediated through stabilization of PHD2, 3 and downregulation of ROS by MSC. Thus, our findings support the development of MSC as a HIF-1α inhibitor in combination chemotherapy. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1238-8Authors Sreenivasulu Chintala, Roswell Park Cancer Institute Department of Cancer Biology Buffalo NY 14263 USAKároly Tόth, Roswell Park Cancer Institute Department of Cancer Biology Buffalo NY 14263 USAShousong Cao, Roswell Park Cancer Institute Department of Cancer Biology Buffalo NY 14263 USAFarukh A. Durrani, Roswell Park... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3168487 Mon, 11 Jan 2010 18:19:40 +0100 3168487 http://www.medworm.com/index.php?rid=3160631&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8h21132860011738%2F Conclusions  The study failed to establish a MTD and was terminated. The presence of PBMC histone acetylation indicates biological activity of vorinostat, however, consistent reductions in intratumoral TS mRNA were not observed. Alternate vorinostat dose-scheduling may alleviate the toxicity and achieve optimal TS downregulation. Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s00280-009-1236-xAuthors Peter M. Wilson, University of Southern California Department of Pathology, Norris Comprehensive Cancer Center, Keck School of Medicine Los Angeles CA 90089 USAAnthony El-Khoueiry, University of Southern California Division of Medical Oncology, Sharon A. Carpenter Laboratory, Norris Comprehensive Cancer Center, Keck School of Medicine Room 5410, 1441... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3160631 Fri, 08 Jan 2010 21:37:06 +0100 3160631 http://www.medworm.com/index.php?rid=3160632&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F07847v236m371587%2F Conclusions  A semi-mechanistic population model was applied to describe the neutropenic effects of BI 2536. The model was used for simulations to support further clinical development. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1223-2Authors Elena Soto, University of Navarra Department of Pharmacy and Pharmaceutical Technology; School of Pharmacy 31080 Pamplona SpainAlexander Staab, Boehringer Ingelheim Pharma GmbH & Co. KG Biberach GermanyChristiane Tillmann, Boehringer Ingelheim Pharma GmbH & Co. KG Biberach GermanyDirk Trommeshauser, Boehringer Ingelheim Pharma GmbH & Co. KG Biberach GermanyHolger Fritsch, Boehringer Ingelheim Pharma GmbH & Co. KG Biberach GermanyGerd Munzert, Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3160632 Fri, 08 Jan 2010 21:37:05 +0100 3160632 http://www.medworm.com/index.php?rid=3160633&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn7577n7281832171%2F Conclusions  These data support ongoing clinical evaluation of voreloxin both alone and in combination with cytarabine for the treatment of AML. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1234-zAuthors Caroline D. Scatena, Sunesis Pharmaceuticals, Inc. 395 Oyster Point Blvd. South San Francisco CA 94080 USAJeffrey L. Kumer, Sunesis Pharmaceuticals, Inc. 395 Oyster Point Blvd. South San Francisco CA 94080 USAJennifer P. Arbitrario, Sunesis Pharmaceuticals, Inc. 395 Oyster Point Blvd. South San Francisco CA 94080 USAAnthony R. Howlett, Sunesis Pharmaceuticals, Inc. 395 Oyster Point Blvd. South San Francisco CA 94080 USARachael E. Hawtin, Sunesis Pharmaceuticals, Inc. 395 Oyster Point Blvd. South San Francisco CA 94080 USAJudith A. Fox, Sun... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3160633 Thu, 07 Jan 2010 22:18:05 +0100 3160633 http://www.medworm.com/index.php?rid=3154196&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fut8144tu56063364%2F Conclusions  The combination carboplatin and pemetrexed is safe and well tolerated. A multicenter phase-II trial is currently underway. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1230-3Authors Jalid Sehouli, Charité University Hospital Department of Obstetrics and Gynecology Campus Virchow 13353 Berlin GermanyOumar Camara, Friedrich Schiller University of Jena Department of Obstetrics and Gynecology Jena GermanySven Mahner, University Medical Center Hamburg-Eppendorf Department of Gynecology Hamburg GermanyThomas Bauknecht, Lilly Deutschland GmbH Medical Department Oncology Bad Homburg GermanyWerner Lichtenegger, Charité University Hospital Department of Obstetrics and Gynecology Campus Virchow 13353 Berlin GermanyIngo Runnebaum, Friedr... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3154196 Wed, 06 Jan 2010 18:04:28 +0100 3154196 http://www.medworm.com/index.php?rid=3154197&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw77w86387341308h%2F Conclusions  The high dose-limiting toxicity rates observed with lenalidomide and weekly paclitaxel require exploration of alternate dose-schedules of the combination in the second-line setting of CRPC. These early observations suggest distinctive toxicity and efficacy outcomes from thalidomide in combination with paclitaxel. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s00280-009-1237-9Authors P. Mathew, University of Texas MD Anderson Cancer Center Department of Genitourinary Medical Oncology Houston TX USAN. Tannir, University of Texas MD Anderson Cancer Center Department of Genitourinary Medical Oncology Houston TX USAS. M. Tu, University of Texas MD Anderson Cancer Center Department of Genitourinary Medical Oncology Houston TX USAC. M. Carte... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3154197 Tue, 05 Jan 2010 16:58:06 +0100 3154197 http://www.medworm.com/index.php?rid=3154198&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl72j5k32n224152u%2F Conclusions  Syl611 is an effective and potential agent in reversing multidrug resistance (MDR) by multiple actions, which attributed to p-glycoprotein inhibition and drug permeability enhancement. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1229-9Authors Yi Zhang, Chinese Academy of Medical Sciences and Peking Union Medical College (Key Laboratory of Biosynthesis of Natural Products, Ministry of Health of PRC and Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education of PRC) Department of Pharmacology, Institute of Materia Medica 1 Xian Nong Tan Street 100050 Beijing People’s Republic of ChinaHongyan Li, Chinese Academy of Medical Sciences and Peking Union Medical College (Key... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3154198 Tue, 05 Jan 2010 16:57:59 +0100 3154198 http://www.medworm.com/index.php?rid=3154199&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F77m8p06g76724403%2F This study evaluated the effect of hepatic impairment on the pharmacokinetics of sunitinib and its active metabolite, SU12662. This open-label study enrolled subjects with normal hepatic function (n = 8), mild (Child–Pugh [CP]-A; n = 8), or moderate (CP-B; n = 8) hepatic impairment. Subjects received sunitinib 50 mg as a single oral dose. Mild or moderate hepatic impairment did not significantly alter sunitinib, SU12662, or total drug (TD) systemic exposure. In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC0–∞ was 1,938, 2,002, and 1,999 ng h/ml, TD AUC0–last was 1,913, 1,956, and 1,958 ng h/ml, and TD C max was 26.0, 27.3, and 26.7 ng/ml. There were no other notable p... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3154199 Mon, 04 Jan 2010 18:15:46 +0100 3154199 http://www.medworm.com/index.php?rid=3136184&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm85614457070w834%2F Conclusions  Oral ABT-751 pharmacokinetics was dose-proportional and age-independent with minimal intra- and inter-patient variability in children. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1218-zAuthors Elizabeth Fox, National Cancer Institute Pediatric Oncology Branch 10 Center Drive, Bldg. 10/Rm. 1-5750 Bethesda MD 20892-1101 USAJohn M. Maris, Center for Childhood Cancer Research at The Children’s Hospital of Philadelphia and University of Pennsylvania School of Medicine Philadelphia PA USASusan L. Cohn, University of Chicago Chicago IL USAWendy Goodspeed, National Cancer Institute Pediatric Oncology Branch 10 Center Drive, Bldg. 10/Rm. 1-5750 Bethesda MD 20892-1101 USAAnne Goodwin, National Cancer Institute Pediatric Oncology Bran... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3136184 Thu, 31 Dec 2009 16:44:50 +0100 3136184 http://www.medworm.com/index.php?rid=3136185&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv26l68x703300059%2F Conclusions  We found that intravenous paclitaxel is active against the metastases of human gastric cancer of peritoneal diffuse type, which warrants further investigations on optimizing the perioperative regimens with intravenous paclitaxel therapy for gastric cancer in patients. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1222-3Authors Tsung-Fan Tuan, National Health Research Institutes Division of Biotechnology and Pharmaceutical Research 35 Keyan Road Zhunan, Miaoli 35053 TaiwanMeng-Li Tsai, National Ilan University Department of Biomechatronic Engineering Ilan TaiwanKai-Chia Yeh, National Health Research Institutes Division of Biotechnology and Pharmaceutical Research 35 Keyan Road Zhunan, Miaoli 35053 TaiwanHsin-Chieh Huang, Nation... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3136185 Thu, 31 Dec 2009 16:44:48 +0100 3136185 http://www.medworm.com/index.php?rid=3134320&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr1652r2331463pu0%2F Conclusions  Oral sunitinib 37.5 mg/day on Schedule 2/1 with docetaxel 75 mg/m2 IV q21d is a clinically feasible regimen with a manageable safety profile, no pharmacokinetic drug–drug interactions, and shows antitumor activity in patients with advanced solid tumors. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1209-0Authors Francisco Robert, University of Alabama at Birmingham, Comprehensive Cancer Center Birmingham AL USAAlan Sandler, Oregon Health & Science University Portland OR USAJoan H. Schiller, University of Texas Southwestern, Division of Hematology and Oncology Dallas TX USAGlenn Liu, University of Wisconsin Carbone Cancer Center Madison WI USAKaren Harper, University of Alabama at Birmingham, Comprehensive Cancer Cen... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3134320 Wed, 30 Dec 2009 16:43:51 +0100 3134320 http://www.medworm.com/index.php?rid=3130561&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd612011w58546263%2F Conclusions  Our data suggest that the combination between sorafenib and long-acting octreotide is active and well tolerated in patients with advanced HCC and could represent another efficacious chance for the management of this population. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1226-zAuthors Salvatore Del Prete, “San Giovanni di Dio” Hospital Medical Oncology Unit Via Giovanni XXII 80020 Frattaminore, Naples ItalyLiliana Montella, “San Giovanni di Dio” Hospital Medical Oncology Unit Via Giovanni XXII 80020 Frattaminore, Naples ItalyMichele Caraglia, Second University of Naples Department of Biochemistry and Biophysics Naples ItalyLuigi Maiorino, Oncology Unit “San Gennaro” Hospital Naples ItalyGregorio Cennamo, “San Gi... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3130561 Tue, 29 Dec 2009 17:54:54 +0100 3130561 http://www.medworm.com/index.php?rid=3130562&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F51t1645031m0x515%2F Conclusion  Our results indicate that several anticancer drugs can activate PXR-mediated induction of Pgp and affect the accumulation of Pgp substrates. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1221-4Authors Stefan Harmsen, Utrecht University Division of Biomedical Analysis, Department of Pharmaceutical Sciences, Faculty of Science Sorbonnelaan 16 3584 CA Utrecht The NetherlandsI. Meijerman, Utrecht University Division of Biomedical Analysis, Department of Pharmaceutical Sciences, Faculty of Science Sorbonnelaan 16 3584 CA Utrecht The NetherlandsC. L. Febus, Utrecht University Division of Biomedical Analysis, Department of Pharmaceutical Sciences, Faculty of Science Sorbonnelaan 16 3584 CA Utrecht The NetherlandsR. F. Maas-Bakker, Utre... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3130562 Tue, 29 Dec 2009 17:54:52 +0100 3130562 http://www.medworm.com/index.php?rid=3130563&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl41j2kj156762533%2F Conclusions  This study demonstrates that CR3294 acts on key molecular targets to reduce the signs of mucositis and the occurrence of diarrhea in mice exposed to the chemotherapy drug 5-fluorouracil. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1224-1Authors Ornella Letari, Department of Pharmacology and Toxicology Rottapharm S.p.A., via Valosa di Sopra 9 20052 Monza ItalyCatherine Booth, Epistem Ltd. 48 Grafton Street Manchester M13 9XX UKAlbino Bonazzi, Department of Clinical Pharmacology Rottapharm S.p.A., via Valosa di Sopra 9 20052 Monza ItalyPaolo Garofalo, Department of Pharmacology and Toxicology Rottapharm S.p.A., via Valosa di Sopra 9 20052 Monza ItalyFrancesco Makovec, Department of Pharmacology and Toxicology Rottapharm S.p.A.,... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3130563 Tue, 29 Dec 2009 17:54:51 +0100 3130563 http://www.medworm.com/index.php?rid=3130564&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl856134561134146%2F Conclusions  DCS combination chemotherapy is highly active against unresectable metastatic gastric cancer and can be given safely with proper management of adverse events. Further studies of this combination are warranted. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1215-2Authors Yasushi Sato, Sapporo Medical University Fourth Department of Internal Medicine, School of Medicine South 1 West 16, Chuo-ku Sapporo 060-8543 JapanTetsuji Takayama, Tokushima University Department of Gastroenterology and Oncology Tokushima JapanTamotsu Sagawa, Sapporo Medical University Fourth Department of Internal Medicine, School of Medicine South 1 West 16, Chuo-ku Sapporo 060-8543 JapanYasuo Takahashi, Hokkaido Cancer Center Department of Gastroenterology Sa... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3130564 Tue, 29 Dec 2009 17:54:50 +0100 3130564 http://www.medworm.com/index.php?rid=3127415&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fmn36855j87648267%2F Conclusion  This study defined a tolerable dose of irinotecan in combination with lomeguatrib in patients with metastatic colorectal cancer. Combination treatment gave a similar response rate to irinotecan monotherapy in this heavily pre-treated patient group. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1225-0Authors A. Sabharwal, University of Oxford Department of Medical Oncology, Churchill Hospital Old Road Oxford OX3 7LJ UKP. G. Corrie, Addenbrooke’s Hospital Oncology Centre Cambridge CB2 0QQ UKR. S. Midgley, University of Oxford Department of Medical Oncology, Churchill Hospital Old Road Oxford OX3 7LJ UKC. Palmer, Addenbrooke’s Hospital Oncology Centre Cambridge CB2 0QQ UKJ. Brady, University of Oxford Department of Medical Onco... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3127415 Mon, 28 Dec 2009 19:12:32 +0100 3127415 http://www.medworm.com/index.php?rid=3125033&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq162725262223m8k%2F Conclusions  Our results suggest that S-1 is an important treatment option for patients with hemodialysis with advanced gastric cancer. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s00280-009-1216-1Authors Nariaki Tomiyama, Izumi General Medical Center Department of Pharmacy 520, Myojin-cho, Izumi-shi Kagoshima 899-0131 JapanMuneaki Hidaka, Kyushu University of Health and Welfare Department of Pharmaceutical Sciences Nobeoka JapanHideo Hidaka, Kagoshima City Hospital Department of Urology Kagoshima JapanYukihiro Kawano, Izumi General Medical Center Department of Urology Kagoshima JapanNorihisa Hanada, Izumi General Medical Center Department of Surgery Kagoshima JapanHideki Kawaguchi, Izumi General Medical Center Division of Radiology, Department of... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3125033 Sat, 26 Dec 2009 16:47:04 +0100 3125033 http://www.medworm.com/index.php?rid=3122740&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff3971451p6757024%2F Conclusions  In this Japanese population, we did not find an evident association between ABCG2 polymorphisms, c.376C > T and c.421C > A, and susceptibility to gefitinib-induced adverse effects. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1211-6Authors Keiichi Akasaka, Dokkyo Medical University Koshigaya Hospital Department of Respiratory Medicine Koshigaya, Saitama JapanTakayuki Kaburagi, Ibaraki Prefectural Central Hospital Department of Respiratory Disease Kasama, Ibaraki JapanShin’ichi Yasuda, Institute for Medical Science, Dokkyo Medical University Mibu, Tochigi JapanKyoko Ohmori, Joint Research Center, Dokkyo Medical University Koshigaya Hospital Koshigaya, Saitama JapanKaori Abe, Ibaraki Prefectural Centra... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3122740 Fri, 25 Dec 2009 00:17:03 +0100 3122740 http://www.medworm.com/index.php?rid=3122741&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx1k12368763v3618%2F Abstract  Small-molecule tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) pathways are used clinically for patients with non-small cell lung cancer (NSCLC). It is well established that somatic mutations in the kinase domain of the EGFR (Lynch et al. in N Engl J Med 350:2129–2139, 2004; Paez et al. in Science 304:1497–1500, 2004) are strongly associated with the tumor response and clinical outcomes in patients with NSCLC receiving EGFR-TKIs (Mitsudomi and Yatabe in Cancer Sci 98:1817–1824, 2007). Although the most common adverse events are skin rash and diarrhea, the most serious adverse effect reported is drug-related interstitial lung disease (ILD) (Inoue et al. in Lancet 361:137–139, 2003; Ando et al. in J Clin Oncol 24:2549–2... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3122741 Fri, 25 Dec 2009 00:17:01 +0100 3122741 http://www.medworm.com/index.php?rid=3122743&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe02197r40u7k3268%2F Conclusions  Down-regulation of HSP70 improves ATO and 17-DMAG effects on constitutive STAT3 activity. These results further provide a basis for studying the combined role of ATO with a HSP90 inhibitor such as 17-DMAG in AML with constitutive STAT3 activity. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1210-7Authors Sampa Ghoshal, Leukemia Section Department of Medicine, Roswell Park Cancer Institute Elm and Carlton Streets Buffalo NY 14263 USAIndranil Rao, State University of New York at Buffalo Department of Pharmaceutical Sciences Buffalo NY USAJustin C. Earp, State University of New York at Buffalo Department of Pharmaceutical Sciences Buffalo NY USAWilliam J. Jusko, State University of New York at Buffalo Department of Pharmaceutical ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3122743 Fri, 25 Dec 2009 00:16:59 +0100 3122743 http://www.medworm.com/index.php?rid=3122742&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn9h2613207863010%2F Conclusions  Copper–indomethacin has both gastrointestinal and renal sparing properties while maintaining efficacy in experimental adenocarcinoma. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1220-5Authors Antonio M. Bonin, The University of Sydney School of Chemistry Sydney NSW 2006 AustraliaJaime A. Yáñez, Washington State University College of Pharmacy, Department of Pharmaceutical Sciences Pullman WA 99164-6534 USAChie Fukuda, Washington State University College of Pharmacy, Department of Pharmaceutical Sciences Pullman WA 99164-6534 USAXiao Wei Teng, Washington State University College of Pharmacy, Department of Pharmaceutical Sciences Pullman WA 99164-6534 USACarolyn T. Dillon, The University of Sydney School of Chemistry Sydney N... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3122742 Fri, 25 Dec 2009 00:16:59 +0100 3122742 http://www.medworm.com/index.php?rid=3122745&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm7485132641w8r66%2F Conclusion  The MMR status or p53 positivity was not significantly associated with outcomes to FOLFOX as adjuvant chemotherapy in colon cancer patients with R0 resection. Adding oxaliplatin in adjuvant chemotherapy may overcome negative impact of 5-FU on colon cancers with MSI-H/MMR-D. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1206-3Authors Seung Tae Kim, Sungkyunkwan University School of Medicine Divisions of Hematology-Oncology, Department of Medicine, Samsung Medical Center 50 Irwon-dong Gangnam-gu, Seoul 135-710 South KoreaJeeyun Lee, Sungkyunkwan University School of Medicine Divisions of Hematology-Oncology, Department of Medicine, Samsung Medical Center 50 Irwon-dong Gangnam-gu, Seoul 135-710 South KoreaSe Hoon Park, Sungkyunkwa... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3122745 Thu, 24 Dec 2009 19:56:08 +0100 3122745 http://www.medworm.com/index.php?rid=3122744&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw8024t556t766475%2F Abstract  We compared concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin (CDDP), and 5-fluorouracil (5-FU) (TPF) with CCRT with CDDP, 5-FU, methotrexate and leucovorin (PFML) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) in terms of safety and efficacy on survival. A total of 100 patients were enrolled. The TPF group received CCRT with the TPF regimen [docetaxel (50 mg/m2: day 1), CDDP (60 mg/m2: day 4), and continuous 5-FU infusion (600 mg/m2/day: days 1–5)]. In the PFML group, patients received CCRT with the PFML regimen [CDDP (60 mg/m2: day 4)], continuous 5-FU infusion (600 mg/m2/day: days 1–5), methotrexate (30 mg/m2: day 1) and leucovorin (20 mg/m2/day: days 1–5)]. Both groups re... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3122744 Thu, 24 Dec 2009 19:56:08 +0100 3122744 http://www.medworm.com/index.php?rid=3122746&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv67552141x11gj86%2F Conclusions  COR-D possesses significant anti-leukemic activity in U937 and HL-60 cell lines by acting on the mitochondrial apoptotic pathways. Since the necrotic body formation is low after COR-D treatment, the occurrence of inflammation in in vivo systems could be reduced, which represents a positive indication in view of therapeutic application. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1214-3Authors Sumana Mallick, Indian Institute of Chemical Biology [A Unit of Council of Scientific & Industrial Research (CSIR), India] Drug Development Division 4, Raja S.C.Mullick Road Kolkata 700032 IndiaPapiya Ghosh, Indian Institute of Chemical Biology [A Unit of Council of Scientific & Industrial Research (CSIR), India] Drug Development Divisi... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3122746 Thu, 24 Dec 2009 19:56:06 +0100 3122746 http://www.medworm.com/index.php?rid=3122747&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fcg8wx87xk8055148%2F Conclusion  Bevacizumab should be administrated systemically compared to regionally, and the combination with i.p. paclitaxel has a potential to be useful for patients with peritoneal metastasis of gastric cancer. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1219-yAuthors Yasumichi Yagi, Kanazawa University Department of Gastroenterologic Surgery, Division of Cancer Medicine, Graduate School of Medical Science 13-1 Takara-machi Kanazawa, Ishikawa 920-8641 JapanSachio Fushida, Kanazawa University Department of Gastroenterologic Surgery, Division of Cancer Medicine, Graduate School of Medical Science 13-1 Takara-machi Kanazawa, Ishikawa 920-8641 JapanShinichi Harada, Kanazawa University Center for Biomedical Research and Education, School of... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3122747 Thu, 24 Dec 2009 19:56:05 +0100 3122747 http://www.medworm.com/index.php?rid=3121216&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5276824264798r36%2F Conclusion  HDMTX does not appear to enhance 6-MP activation to 6-TGN. Moreover, given that the deleterious effect of HDMTX on intracellular 6-MP disposition has been shown to be several folds greater in lymphoblasts than in RBC. Our data warrant additional studies elucidating the optimal MTX dose synergizing with 6-MP. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1205-4Authors T. Adam de Beaumais, Robert Debre Hospital Department of Pediatric Pharmacology and Pharmacogenetics 48 Boulevard Serurier 75019 Paris FranceT. Dervieux, Cypress Bioscience San Diego CA USAM. Fakhoury, Robert Debre Hospital Department of Pediatric Pharmacology and Pharmacogenetics 48 Boulevard Serurier 75019 Paris FranceY. Medard, Robert Debre Hospital Department o... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3121216 Wed, 23 Dec 2009 22:15:24 +0100 3121216 http://www.medworm.com/index.php?rid=3121217&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5576h8427773g757%2F Conclusions  CCRT regimen using cisplatin and 5-FU followed by three cycles of BEC chemotherapy was effective in locally advanced NPC patients, with acceptable and reversible acute toxicities. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1203-6Authors Kyong Hwa Park, Korea University College of Medicine Division of Oncology/Hematology, Department of Internal Medicine 126-1, Anam-dong 5 ga, Seongbuk-gu Seoul 136-705 KoreaJeong Sun Kim, Korea University College of Medicine Division of Oncology/Hematology, Department of Internal Medicine 126-1, Anam-dong 5 ga, Seongbuk-gu Seoul 136-705 KoreaYong Park, Korea University College of Medicine Division of Oncology/Hematology, Department of Internal Medicine 126-1, Anam-dong 5 ga, Seongbuk-gu Seoul ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3121217 Wed, 23 Dec 2009 22:15:21 +0100 3121217 http://www.medworm.com/index.php?rid=3108994&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff6178438022x5j74%2F Conclusion  The antitumor activity and the promising pharmacological profile indicate gimatecan as an excellent candidate for clinical treatment of pediatric tumors. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1201-8Authors Massimo Zucchetti, Istituto di Ricerche Farmacologiche “Mario Negri” Department of Oncology Via La Masa 19 20156 Milan ItalyDaniela Meco, Catholic University of Rome Division of Pediatric Oncology Largo A. Gemelli 8 00168 Rome ItalyAngela Maria Di Francesco, Catholic University of Rome Division of Pediatric Oncology Largo A. Gemelli 8 00168 Rome ItalyTiziana Servidei, Catholic University of Rome Division of Pediatric Oncology Largo A. Gemelli 8 00168 Rome ItalyValentina Patriarca, Catholic University of Rome Divisi... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3108994 Sat, 19 Dec 2009 16:43:37 +0100 3108994 http://www.medworm.com/index.php?rid=3108995&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7622010311303m35%2F Conclusions  While the development and approval of the HER2-targeted recombinant monoclonal antibody trastuzumab (Herceptin) has been efficacious in slowing HER2 cancer progression, combining this and other anti-HER2 therapy with either chemotherapy or endocrine therapy has proven more effective in improving overall and progression free survival. Content Type Journal ArticleCategory Mini ReviewDOI 10.1007/s00280-009-1208-1Authors April Davoli, Wright State University Boonshoft School of Medicine Laboratory of Cell Death, Differentiation, and Development, Department of Neuroscience, Cell Biology, and Physiology 3640 Colonel Glenn Highway, 011 Medical Sciences Building Dayton OH 45435 USABarbara A. Hocevar, Indiana University School of Medicine Department of Pharmacology... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3108995 Sat, 19 Dec 2009 16:43:36 +0100 3108995 http://www.medworm.com/index.php?rid=3105944&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F45pu18121171726l%2F Conclusion  These data demonstrate that oxaliplatin and pemetrexed synergistically interact against colon cancer cells, through modulation of cell cycle, inhibition of Akt phosphorylation, induction of apoptosis and modulation of gene expression. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1195-2Authors Sara Nannizzi, University of Pisa Division of Pharmacology and Chemotherapy, Department of Internal Medicine 56126 Pisa ItalyGareth J. Veal, Newcastle University Northern Institute for Cancer Research, Medical School Newcastle upon Tyne NE2 4HH UKElisa Giovannetti, University of Pisa Division of Pharmacology and Chemotherapy, Department of Internal Medicine 56126 Pisa ItalyValentina Mey, University of Pisa Division of Pharmacology and Chem... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3105944 Fri, 18 Dec 2009 07:05:47 +0100 3105944 http://www.medworm.com/index.php?rid=3105945&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F35429x1n134144v5%2F Conclusion  Our results suggest that pro-apoptotic PBOX compounds may be potential candidates for the treatment of P-glycoprotein- or BCRP-associated MDR cancers. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1200-9Authors Seema-Maria Nathwani, Trinity College School of Biochemistry and Immunology Dublin 2 IrelandStephen Butler, Trinity College School of Pharmacy and Pharmaceutical Sciences Dublin 2 IrelandDarren Fayne, Trinity College Molecular Design Group, School of Biochemistry and Immunology Dublin 2 IrelandNaomi N. McGovern, Trinity College School of Biochemistry and Immunology Dublin 2 IrelandBalazs Sarkadi, Semmelweis University and National Blood Center Membrane Research Group of Hungarian Academy of Sciences Budapest HungaryMary J... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3105945 Fri, 18 Dec 2009 07:05:45 +0100 3105945 http://www.medworm.com/index.php?rid=3097672&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft38458q67j870524%2F Conclusion  Paclitaxel combined with ifosfamide was effective and tolerable in anthracycline-/docetaxel-pretreated MBC. Overcoming docetaxel resistance by using paclitaxel in combination with ifosfamide needs to be addressed through further investigation. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1176-5Authors Yong Wha Moon, Yonsei University College of Medicine Department of Internal Medicine, Yonsei Cancer Center 250 Seongsanno, Seodaemun-gu Seoul 120-752 KoreaJoo Hyuk Sohn, Yonsei University College of Medicine Department of Internal Medicine, Yonsei Cancer Center 250 Seongsanno, Seodaemun-gu Seoul 120-752 KoreaHye Jin Choi, Yonsei University College of Medicine Department of Internal Medicine, Yonsei Cancer Center 250 Seongsanno, Se... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3097672 Tue, 15 Dec 2009 06:46:25 +0100 3097672 http://www.medworm.com/index.php?rid=3090186&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr272l01j1q8u21q8%2F Conclusion  These data suggest that small molecule inhibitors of Hsc70/Hsp70 phenotypically mimic the cellular mode of action of a small molecule Hsp90 inhibitor and can potentiate the apoptotic potential of a small molecule Hsp90 inhibitor in certain cell lines. The factors determining whether or not cells apoptose in response to Hsp90 inhibition or the combination of Hsp90 plus Hsc70/Hsp70 inhibition remain to be determined. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1194-3Authors Andrew J. Massey, Vernalis (R&D) Ltd Granta Park Cambridge CB21 6GB UKDouglas S. Williamson, Vernalis (R&D) Ltd Granta Park Cambridge CB21 6GB UKHelen Browne, Vernalis (R&D) Ltd Granta Park Cambridge CB21 6GB UKJames B. Murray, Vernalis (R&D) Ltd Granta Par... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3090186 Sun, 13 Dec 2009 06:47:11 +0100 3090186 http://www.medworm.com/index.php?rid=3090187&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm9243423565k41mr%2F Conclusions  Epoetin-beta (EB) treatment in our series of patients with digestive malignancies subjected to neoadjuvant radiochemotherapy proved effective and safe, avoiding the need for transfusion during surgery. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1197-0Authors Antonio Gómez, Hospital Clínico Universitario Santiago de Compostela Servicio Oncología Radioterápica Travesia Choupana S/N 15706 Santiago de Compostela SpainMercedes Salgado, Complejo Hospitalario de Orense Servicio Oncología Médica Orense SpainManuel Valladares-Ayerbes, Complejo Hospitalario de La Coruña Servicio Oncología Médica La Coruña SpainMónica Jorge, Complejo Hospitalario de Vigo Servicio Oncología Médica Vigo SpainAna Carballo, Hospital Clínico U... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3090187 Sat, 12 Dec 2009 14:15:55 +0100 3090187 http://www.medworm.com/index.php?rid=3090189&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk8q8774001m7v83h%2F Conclusions  Aminoflavone is a promising therapeutic agent for breast cancer due to its unique mechanism of action compared to commonly used drugs. Combined treatments utilizing aminoflavone in conjunction with paclitaxel or camptothecin may provide an even greater cytotoxic effect than achieved with aminoflavone alone. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1198-zAuthors Kathryn E. Reinicke, Mayo Clinic Department of Oncology Rochester MN 55905 USAMary J. Kuffel, Mayo Clinic Department of Oncology Rochester MN 55905 USAMatthew P. Goetz, Mayo Clinic Department of Oncology Rochester MN 55905 USAMatthew M. Ames, Mayo Clinic Department of Oncology Rochester MN 55905 USA Journal Cancer Chemotherapy and PharmacologyOnline ISSN 143... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3090189 Thu, 10 Dec 2009 15:15:46 +0100 3090189 http://www.medworm.com/index.php?rid=3090188&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu318034h25721570%2F Conclusions  PR-104 was well tolerated at a dose of 1,100 mg/m2 administered as an IV infusion every 3 weeks. The area under the PR-104A plasma concentration–time curve at this dose exceeded that required for activity in human tumor cell cultures and xenograft models. The recommended dose of PR-104 as a single agent for phase II trials is 1,100 mg/m2 and further trials are underway. Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s00280-009-1188-1Authors Michael B. Jameson, Waikato Hospital Regional Cancer Centre Private Bag 3200 Hamilton 3240 New ZealandDanny Rischin, Peter MacCallum Cancer Centre Melbourne AustraliaMark Pegram, University of California, Los Angeles Los Angeles CA USAJohn Gutheil, Proacta Inc. San Diego CA USAAda... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3090188 Thu, 10 Dec 2009 15:15:46 +0100 3090188 http://www.medworm.com/index.php?rid=3064126&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc88512234jq48582%2F Conclusions  The results of this meta-analysis indicate that increased exposure to sunitinib is associated with improved clinical outcomes (longer TTP, longer OS, greater chance of antitumor response), as well as some increased risk of adverse effects. A sunitinib 50-mg starting dose seems reasonable, providing clinical benefit with acceptably low risk of adverse events. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1170-yAuthors Brett E. Houk, Pfizer Inc., Global Research and Development 10578 Science Center Drive, CB1 San Diego CA 92121 USACarlo L. Bello, Pfizer Inc., Global Research and Development 10578 Science Center Drive, CB1 San Diego CA 92121 USABill Poland, Pharsight Corp 321 E Evelyn Ave Mountain View CA 94041 USALee S. Rosen, P... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3064126 Sat, 05 Dec 2009 08:58:30 +0100 3064126 http://www.medworm.com/index.php?rid=3064125&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl434h23101278049%2F Conclusions  The regimen of induction chemotherapy with gemcitabine and S-1 followed by chemoradiotherapy used in the present study demonstrated promising activity in locally advanced pancreatic cancer. Further consideration of radiation schedule and duration of induction chemotherapy is required to enhance the efficacy of this strategy. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1193-4Authors Kohei Nakachi, National Cancer Center Hospital East Divisions of Hepatobiliary and Pancreatic Oncology 6-5-1 Kashiwanoha Kashiwa Chiba 277-8577 JapanJunji Furuse, Kyorin University School of Medicine Department of Internal Medicine, Medical Oncology Tokyo JapanTaira Kinoshita, National Cancer Center Hospital East Division of Upper Abdominal Surger... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3064125 Sat, 05 Dec 2009 08:58:30 +0100 3064125 http://www.medworm.com/index.php?rid=3080334&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw740j80522324646%2F Conclusions  Pretreatment with 5FU enhanced the MMC-induced toxicity against gastric cancer cells via alterations in antioxidant enzymes with resulting ROS generation. This observation will need confirmation in the clinical setting. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1192-5Authors Toshiyuki Matsunaga, Gifu Pharmaceutical University Laboratory of Biochemistry Gifu 502-8585 JapanYoshitaka Tsuji, Saitama Medical University Department of Surgery Saitama JapanKairyu Kaai, Saitama Medical University Department of Surgery Saitama JapanSaki Kohno, Gifu Pharmaceutical University Laboratory of Biochemistry Gifu 502-8585 JapanRenzo Hirayama, Saitama Medical University Department of Surgery Saitama JapanDavid H. Alpers, Washington University... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3080334 Fri, 04 Dec 2009 21:14:27 +0100 3080334 http://www.medworm.com/index.php?rid=3064127&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc730191515247507%2F Conclusion  Treatment with tipifarnib relapsed or refractory MCL is associated with low response rates. Limited gene expression studies suggest that response may be associated with molecular targets. Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s00280-009-1185-4Authors Delphine Rolland, Universite Joseph Fourier INSERM U836 Equipe 7, Faculte de Medecine Grenoble FranceVincent Ribrag, Institut Gustave Roussy Departement de Medecine Villejuif FranceCorinne Haioun, Henri Mondor Hopital Department of Hematology Creteil FranceHerve Ghesquieres, Centre Leon Berard Department of Hematology Lyon FranceFabrice Jardin, INSERM U918, Centre Henri Becquerel Department of Hematology Rouen FranceReda Bouabdallah, Université de la Méditerranée Department of ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3064127 Thu, 03 Dec 2009 18:20:39 +0100 3064127 http://www.medworm.com/index.php?rid=3064128&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F44448811h252126j%2F Conclusions  This is the first study which showed that polymorphisms of ERCC1 and XRCC1, in combination not individually, were independent predictors for DCR and OS. This may contribute to the selection of patients who would benefit from oxaliplatin-based chemotherapy for metastatic colorectal cancer. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1186-3Authors Jun Liang, Qing Dao University Department of Oncology, The Affiliated Hospital of Medical College 266003 Qingdao ChinaTao Jiang, Qing Dao University Department of Oncology, The Affiliated Hospital of Medical College 266003 Qingdao ChinaRu-yong Yao, Qing Dao University Central Laboratory, The Affiliated Hospital of Medical College 266003 Qingdao ChinaZi-min Liu, Qing Dao University De... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3064128 Thu, 03 Dec 2009 18:20:38 +0100 3064128 http://www.medworm.com/index.php?rid=3064130&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk862j8x87m260256%2F Conclusions  This is the first study evaluating the effect of the RAD51 G135C polymorphism in NSCLC patient survival. Our results suggest that RAD51 genotypes could be useful molecular markers for predicting the clinical outcome of NSCLC patients. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1187-2Authors Augusto Nogueira, Instituto Português de Oncologia Molecular Oncology Unit, Portuguese Institute of Oncology Laboratórios—Piso 4, R. Dr. Ant. Bernardino Almeida 4200-072 Porto PortugalRaquel Catarino, Instituto Português de Oncologia Molecular Oncology Unit, Portuguese Institute of Oncology Laboratórios—Piso 4, R. Dr. Ant. Bernardino Almeida 4200-072 Porto PortugalAna Coelho, Instituto Português de Oncologia Molecular Oncology Uni... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3064130 Thu, 03 Dec 2009 18:20:36 +0100 3064130 http://www.medworm.com/index.php?rid=3064129&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu631r56728411801%2F Conclusions  Velcade targets cell cycle and apoptosis signaling to suppress MPM and HBC growth in part by activating novel transducers of apoptosis. This pilot study has paved way for further in-depth analysis of the downstream target molecules associated with presensitization of mesothelioma cells in finding effective therapeutic treatment options for both mesothelioma and recalcitrant breast cancers. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1181-8Authors Ying Wang, Wayne State University John D. Dingell VA Medical Center, Karmanos Cancer Institute VAMC, 4646 John R. Detroit MI 48201 USAArun K. Rishi, Wayne State University John D. Dingell VA Medical Center, Department of Internal Medicine, Karmanos Cancer Institute Room B4334, VAMC... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3064129 Thu, 03 Dec 2009 18:20:36 +0100 3064129 http://www.medworm.com/index.php?rid=3064132&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F72556r2q305x7476%2F Conclusions  DNA-6TGN may prove to be a more relevant pharmacokinetic parameter for monitoring 6MP treatment intensity than the previously used erythrocyte 6MP metabolites levels. Prospective clinical trials are needed to evaluate the usefulness of DNA-6TGN for individual dose adjustments. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1184-5Authors Rikke L. Hedeland, Rigshospitalet The Section for Pediatric Hematology and Oncology, Pediatric Clinic II, The Juliane Marie Center, The University Hospital 2100 Copenhagen DenmarkKristian Hvidt, Rigshospitalet The Section for Pediatric Hematology and Oncology, Pediatric Clinic II, The Juliane Marie Center, The University Hospital 2100 Copenhagen DenmarkJacob Nersting, Rigshospitalet The Section ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3064132 Thu, 03 Dec 2009 12:49:10 +0100 3064132 http://www.medworm.com/index.php?rid=3064131&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff04762h23lk6j8n5%2F Conclusions  Our study shows that HER2-overexpressing breast cancer displays characteristic patterns of relapse and metastatic spread depending on ER status. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1190-7Authors Yeon Hee Park, Sungkyunkwan University School of Medicine Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center 50 Irwon-dong, Gangnam-gu Seoul 135-710 KoreaSoohyeon Lee, Sungkyunkwan University School of Medicine Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center 50 Irwon-dong, Gangnam-gu Seoul 135-710 KoreaEun Yoon Cho, Sungkyunkwan University School of Medicine Department of Pathology, Samsung Medical Center Seoul KoreaYoon La Choi, Sungkyunkwan University School of Med... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3064131 Thu, 03 Dec 2009 12:49:10 +0100 3064131 http://www.medworm.com/index.php?rid=3064133&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6372437765463520%2F Conclusions  A 100 mg single IV dose of erlotinib, given as a 30-min infusion, was well tolerated with only minor adverse events and the high level of bioavailability of oral erlotinib was confirmed. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1133-3Authors M. Ranson, University of Manchester, Christie Hospital NHS Foundation Trust Department of Medical Oncology Wilmslow Road, Withington Manchester M20 4BX UKH. Shaw, Royal Marsden Hospital London UKJ. Wolf, OSI Pharmaceuticals, Inc. Melville NY USAM. Hamilton, OSI Pharmaceuticals, Inc. Melville NY USAS. McCarthy, OSI Pharmaceuticals, Inc. Melville NY USAE. Dean, University of Manchester, Christie Hospital NHS Foundation Trust Department of Medical Oncology Wilmslow Road, Withington M... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3064133 Thu, 03 Dec 2009 12:49:09 +0100 3064133 http://www.medworm.com/index.php?rid=3040642&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F11286878307378k8%2F Conclusions  The MTD for weekly paclitaxel plus daily PTK/ZK is 75 mg/m2 and 750 mg. PK analysis revealed a significant drug–drug interaction, with an increase in paclitaxel clearance. This combination was well tolerated with evidence of anti-cancer activity and provides guidance for phase 2 planning. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1179-2Authors E. Gabriela Chiorean, Indiana University Simon Cancer Center Department of Medicine Indianapolis IN USASrikar Malireddy, Indiana University Simon Cancer Center Department of Medicine Indianapolis IN USAAnne E. Younger, Indiana University Simon Cancer Center Department of Medicine Indianapolis IN USADavid R. Jones, Indiana University Simon Cancer Center Department of Medici... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3040642 Sun, 29 Nov 2009 09:31:34 +0100 3040642 http://www.medworm.com/index.php?rid=3040643&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7u23085j342q1387%2F Abstract  Nrf2 is a key transcription factor, which induces a cytoprotective gene array. Nrf2 is regulated at the posttranslational level through proteasomal degradation through an interaction with the adapter protein Keap1. High levels of Nrf2, resulting from a loss of function mutation in Keap1, were reported in chemoresistant non-small cell lung cancer. We observed very low levels of Nrf2 and of Nrf2-regulated detoxification proteins as a frequent phenotype in the more chemosensitive breast cancer, and when engineering increased Nrf2 levels, we found resistance to both doxorubicin and paclitaxel. We here show that basal Nrf2 levels in different cell lines correlate with their respective sensitivity to a common cytotoxic chemotherapy. Nrf2 and its regulated genes and prot... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3040643 Thu, 26 Nov 2009 07:58:28 +0100 3040643 http://www.medworm.com/index.php?rid=3040644&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx2438j8731730200%2F Conclusion  The present findings demonstrate that Se-induced apoptosis in carcinoma cells is basically a caspase-dependent process involving complicated mechanisms. Activation of both the intrinsic apoptotic pathway and ER stress pathway plays a major and concurrent role, while p53 activation seems to have only a functional role in SeMet. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1183-6Authors Maiko Suzuki, Tohoku University Graduate School of Dentistry Department of Microbiology and Immunology 4-1 Seiryo-machi, Aoba-ku Sendai 980-8575 JapanManabu Endo, Tohoku University Graduate School of Dentistry Department of Microbiology and Immunology 4-1 Seiryo-machi, Aoba-ku Sendai 980-8575 JapanFumiaki Shinohara, Tohoku University Graduate Sch... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3040644 Thu, 26 Nov 2009 07:58:27 +0100 3040644 http://www.medworm.com/index.php?rid=3031637&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm6033743k4728qk2%2F Conclusions  Further studies of the combination of brostallicin and cisplatin are warranted. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1175-6Authors F. Caponigro, National Tumor Institute Naples ItalyD. Lorusso, Catholic University Rome ItalyG. Fornari, Valdese Hospital Torino ItalyC. Barone, Catholic University Rome ItalyM. Merlano, S. Croce e Carle Hospital Cuneo ItalyM. Airoldi, S. Giovanni Antica Sede Hospital Torino ItalyM. Schena, S. Giovanni Battista Hospital Torino ItalyR. MacArthur, Columbia University Research Pharmacy 161 Fort Washington Ave. New York NY 10032 USAS. Weitman, MCS 14358 N. Frank Lloyd Wright Blvd. Scottsdale AZ 85260 USAM. G. Jannuzzo, Nerviano Medical Sciences Nerviano ItalyS. Crippa, Nerviano Medical Sciences... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3031637 Mon, 23 Nov 2009 17:13:05 +0100 3031637 http://www.medworm.com/index.php?rid=3031638&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2gp57105843675u5%2F Conclusions  The combination of carboplatin with weekly docetaxel is a tolerated treatment modality with encouraging activity and survival outcome in previously untreated patients with advanced NSCLC. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1180-9Authors Lian Jiang, Nantong University Department of Respiratory Medicine, Jiangyin People’s Hospital No. 163, Shoushan Rd 214400 Jiangyin Jiangsu People’s Republic of ChinaDao-yuan Wang, Nantong University Department of Respiratory Medicine, Jiangyin People’s Hospital No. 163, Shoushan Rd 214400 Jiangyin Jiangsu People’s Republic of ChinaZhi-hua Zhu, Sun Yat-sen University Department of Thoracic Oncology, State Key Laboratory of Oncology in South China, Cancer Center, Lung Cancer Res... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3031638 Mon, 23 Nov 2009 16:53:14 +0100 3031638 http://www.medworm.com/index.php?rid=3031639&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg51k1lp4j2046221%2F Abstract  We have previously shown that the expression of glucosylceramide synthase (GCS) gene in drug-resistant K562/AO2 human leukemia cell was higher than that in drug-sensitive K562 cell, and the sensitivity to adriamycin of K562/AO2 cell was enhanced by inhibiting GCS. It is concluded that the overexpression of GCS gene is one of the reasons which lead to multidrug resistance (MDR) of leukemia cell. Meanwhile, we also found that higher expression of Bcl-2 gene and protein were exhibited in K562/AO2 cell compared with K562 cell. Basing on this, we hypothesized that the high expression of GCS gene which results in MDR of leukemia cell is correlated with Bcl-2 signal transduction. In order to validate the hypothesis, the inhibition of GCS gene in K562/AO2 cell was observed... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3031639 Mon, 23 Nov 2009 16:48:25 +0100 3031639 http://www.medworm.com/index.php?rid=3019950&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft155402657u735lj%2F Conclusion  The RD of the DXO regimen in patients with AGC is capecitabine 1,000 mg/m2 twice daily on days 1–14, in combination with decetaxel 60 mg/m2 (day 1) and oxaliplatin 100 mg/m2 (day 1) repeated every 3 weeks. The DXO regimen seems to have promising activity and offers an easy alternative to DCF. The toxicities appear to be still substantial, but manageable. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1171-xAuthors Sun Jin Sym, University of Ulsan College of Medicine Division of Oncology, Department of Medicine, Asan Medical Center 388-1 Pungnap-2 Dong, Songpa Gu Seoul 138-736 KoreaMin-Hee Ryu, University of Ulsan College of Medicine Division of Oncology, Department of Medicine, Asan Medical Center 388-1 Pung... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3019950 Sat, 21 Nov 2009 09:08:03 +0100 3019950 http://www.medworm.com/index.php?rid=3009556&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw643v10414066319%2F Conclusion  Combined inhibition of IGFR signaling enhances the growth inhibitory and apoptosis-inducing effects of gefitinib, suggesting that this approach could be useful to overcome the primary resistance to EGFR-TKIs in lung cancer. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1174-7Authors Yun Jung Choi, Korea Institute of Radiological and Medical Science Department of Internal Medicine, Korea Cancer Center Hospital 215-4 Gongneung-dong, Nowon-gu Seoul 139-706 KoreaJin Kyung Rho, Korea Institute of Radiological and Medical Science Department of Internal Medicine, Korea Cancer Center Hospital 215-4 Gongneung-dong, Nowon-gu Seoul 139-706 KoreaByung-suk Jeon, Korea Institute of Radiological and Medical Science Department of Internal Medic... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3009556 Wed, 18 Nov 2009 00:06:21 +0100 3009556 http://www.medworm.com/index.php?rid=3009557&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd05p553543293689%2F Conclusion  These results suggest that the anticancer effect of S-1 can be predicted by performing UrBT 3 h after the initial oral S-1 administration. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1168-5Authors Yukimoto Ishii, Nihon University School of Medicine Department of Surgery, Nerima Hikarigaoka Hospital 2-11-1 Hikarigaoka Nerima-ku Tokyo 179-0072 JapanShigeru Suzuki, Nihon University School of Medicine Division of Genetic and Genomic Research, Medical Research Center Itabashi-ku Tokyo 173-8610 JapanYasuo Takahashi, Nihon University School of Medicine Division of Genetic and Genomic Research, Medical Research Center Itabashi-ku Tokyo 173-8610 JapanTadatoshi Takayama, Nihon University School of Medicine Division of Digestive Sur... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=3009557 Wed, 18 Nov 2009 00:06:19 +0100 3009557 http://www.medworm.com/index.php?rid=2996700&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw1u2j8j8r54rv7g3%2F Conclusions  Genomic analysis provided further evidence that mitochondria are the primary target of doxorubicin-induced oxidative damage that leads to cardiomyopathy and the primary site of cardioprotective action by dexrazoxane. Additional strategies that prevent the formation of oxygen radicals by doxorubicin in mitochondria may provide increased cardioprotection. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1164-9Authors Karol L. Thompson, US Food and Drug Administration Center for Drug Evaluation and Research LSB64 Room 2036, 10903 New Hampshire Avenue Silver Spring MD 20993 USABarry A. Rosenzweig, US Food and Drug Administration Center for Drug Evaluation and Research 10903 New Hampshire Avenue Silver Spring MD 20993 USAJun Zhang, US... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2996700 Fri, 13 Nov 2009 18:21:46 +0100 2996700 http://www.medworm.com/index.php?rid=2990235&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe7n1241w60717257%2F Conclusion  Renal impairment did increase the systemic exposure to arsenic and its methylated metabolites following standard daily dosing of arsenic trioxide. The data from the limited number of patients with severe renal dysfunction did not suggest that severe renal impairment affected the safety profile of arsenic trioxide in cancer patients who received limited treatment with arsenic trioxide. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1169-4Authors Christopher J. Sweeney, Indiana University Department of Medicine 535 Barnhill Drive, Rm 473 Indianapolis IN 46202 USAChris Takimoto, Cancer Therapy and Research Center Institute for Drug Development San Antonio TX USALeslie Wood, Cancer Therapy and Research Center Institute for Drug Dev... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2990235 Thu, 12 Nov 2009 18:37:32 +0100 2990235 http://www.medworm.com/index.php?rid=2986125&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F116321530u075383%2F Conclusions  Albendazole was well tolerated on the schedule tested in this trial. The results of this study suggest that the recommended dose for further study is 1,200 mg twice daily for 14 days in a 21-day cycle. Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s00280-009-1157-8Authors Mohammad H. Pourgholami, University of New South Wales Department of Surgery, St George Clinical School Kogarah, Sydney AustraliaMichael Szwajcer, St George Hospital Cancer Care Cancer Pharmacology and Therapeutics Sydney AustraliaMelvin Chin, St George Hospital Cancer Care Cancer Pharmacology and Therapeutics Sydney AustraliaWinston Liauw, St George Hospital Cancer Care Cancer Pharmacology and Therapeutics Sydney AustraliaJonathan Seef, Southern Radiolo... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2986125 Wed, 11 Nov 2009 07:05:32 +0100 2986125 http://www.medworm.com/index.php?rid=2986126&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fmw7410672gv32110%2F Conclusion  We established in vivo trastuzumab PD models, in which trastuzumab monotherapy ceases to have antitumor activity during the treatment. The mechanisms of PD with trastuzumab are considered to involve both reversible changes in the gene expression profiles in tumor tissues and a decrease of ADCC activity in the host. Our present results demonstrated that trastuzumab showed antitumor activity in combination with taxanes or capecitabine even though it showed no antitumor activity as a monotherapy, suggesting a clinical relevance of treatment with trastuzumab as a combination therapy beyond PD. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1160-0Authors Kaori Fujimoto-Ouchi, Chugai Pharmaceuticals Co., Ltd Product Research Departm... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2986126 Tue, 10 Nov 2009 18:44:51 +0100 2986126 http://www.medworm.com/index.php?rid=2986127&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd87g81415u611141%2F In this report, we describe a fatal gemcitabine-induced pulmonary toxicity in a patient with gallbladder metastatic adenocarcinoma. A 72-year-old patient was submitted to an elective laparoscopic cholecystectomy, and a tubular adenocarcinoma in the gallbladder was incidentally diagnosed. CT scan and ultrasound before the surgery did not show any tumor. After the surgery a Pet scan was positive for a hot-spot in the left colon. The colonic lesion was conveniently removed and the histology evaluation confirmed the diagnosis of adenocarcinoma tubular. The patient was then submitted to three sections of 1,600 mg/m2 of gemcitabine with intervals of 1 week. Three weeks later he developed severe respiratory distress. A helicoidal CT scan showed diffuse and severe interstitial pneumonit... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2986127 Tue, 10 Nov 2009 18:44:50 +0100 2986127 http://www.medworm.com/index.php?rid=2974711&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F42478v01656651gl%2F Conclusions  These data indicate that GLN supplement is able to reduce DOX-induced cardiac damage and thus to enhance DOX therapeutic effectiveness. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1165-8Authors Valentina K. Todorova, University of Arkansas for Medical Sciences (UAMS) Division of Breast Surgical Oncology, Department of Surgery 4301W, Markham St., Mail Slot 725 Little Rock AR USAYihong Kaufmann, Central Arkansas Veterans Healthcare System Little Rock AR USALeah J. Hennings, University of Arkansas for Medical Sciences (UAMS) Department of Pathology Little Rock AR USAV. Suzanne Klimberg, University of Arkansas for Medical Sciences (UAMS) Division of Breast Surgical Oncology, Department of Surgery 4301W, Markham St., Mail Slot 725 ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2974711 Sat, 07 Nov 2009 19:23:14 +0100 2974711 http://www.medworm.com/index.php?rid=2971439&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr3089363034815h2%2F Conclusion  UCN-01 can be safely administered in combination with prednisone without unacceptable toxicity. The prolonged stable disease in two patients with lymphoid malignancies is a proof of principle for the evaluation of cyclin-dependent kinase inhibitors in oncology. Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s00280-009-1154-yAuthors Shivaani Kummar, National Cancer Institute Center for Cancer Research 10 Center Drive Bethesda MD 20892 USAMartin E. Gutierrez, National Cancer Institute Center for Cancer Research 10 Center Drive Bethesda MD 20892 USAErin R. Gardner, Science Applications International Corporation-Frederick, Inc, National Cancer Institute-Frederick Frederick MD USAWilliam D. Figg, National Cancer Institute Center for Cancer... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2971439 Thu, 05 Nov 2009 18:57:21 +0100 2971439 http://www.medworm.com/index.php?rid=2951696&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F01151127567314u8%2F Conclusions  The PSA response rate was promising and the toxicity of DGP was manageable; however OS was comparable to results of treatment with single agent docetaxel. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1163-xAuthors Trine Zeeberg Buch-Hansen, Herlev University Hospital Department of Oncology Herlev Ringvej 75 2730 Herlev DenmarkLise Bentzen, Aarhus University Hospital Department of Oncology Aarhus DenmarkSteinbjoern Hansen, Odense University Hospital Department of Oncology Odense DenmarkMorten Hoeyer, Aarhus University Hospital Department of Oncology Aarhus DenmarkNiels Viggo Jensen, Odense University Hospital Department of Oncology Odense DenmarkCharlotte Saxe, Herlev University Hospital Department of Oncology Herlev Ringvej 75... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2951696 Sat, 31 Oct 2009 12:52:49 +0100 2951696 http://www.medworm.com/index.php?rid=2940764&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb56v5791x8385387%2F Abstract  We investigated various combination treatment regimens employing nilotinib with established chemotherapeutic agents (daunorubicin, mitoxantrone, etoposide and cytarabine) in imatinib-sensitive and -resistant BCR-ABL-positive cells. Mitoxantrone or cytarabine showed synergism (CI < 1) in combination with nilotinib in imatinib-sensitive LAMA84 cells, whereas in imatinib-resistant LAMA84-R cells synergistic effects could be assessed for daunorubicin, mitoxantrone and etoposide when combined with nilotinib. In both imatinib-sensitive and -resistant K562 cells daunorubicin, mitoxantrone and etoposide demonstrated synergism in combination with nilotinib. Moreover, both daunorubicin and mitoxantrone led to synergistic antiproliferative effects when combined w... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2940764 Wed, 28 Oct 2009 07:09:50 +0100 2940764 http://www.medworm.com/index.php?rid=2928314&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F133j85xvqx6x9226%2F Conclusions  The recommended phase II dose of imexon is 875 mg/m² with gemcitabine 1,000 mg/m2. DLT was acute abdominal pain and cramping. Encouraging antitumor responses support further evaluation of this combination in advanced pancreatic cancer. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1162-yAuthors Steven J. Cohen, Fox Chase Cancer Center Department of Medical Oncology 333 Cottman Avenue, Room C307 Philadelphia PA 19111-2497 USAMark M. Zalupski, University of Michigan Ann Arbor USAManuel R. Modiano, Arizona Clinical Research Center Tucson USAPaul Conkling, Virginia Oncology Associates, US Oncology Phase I Group Fairfax USAYehuda Z. Patt, University of New Mexico Albuquerque USAPeg Davis, University of Arizona Tucson USAR... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2928314 Fri, 23 Oct 2009 18:52:59 +0100 2928314 http://www.medworm.com/index.php?rid=2928315&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg17368152x51lp21%2F Conclusions  The pre-determined criteria were not applicable, in their entirety, in the majority of drugs, due to lack of information in the academic domain, emphasising the importance of a more open approach for sharing basic drug information. The prioritised list of 12 candidate drugs for clinical trial and 15 for pre-clinical investigation justify that a concerted research effort in this area of practice is made. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1127-1Authors Sharon Conroy, University of Nottingham Children’s Brain Tumour Research Centre University Park Nottingham NG7 2RD UKMartin Garnett, University of Nottingham Children’s Brain Tumour Research Centre University Park Nottingham NG7 2RD UKMichael Vloeberghs, Universit... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2928315 Fri, 23 Oct 2009 18:52:56 +0100 2928315 http://www.medworm.com/index.php?rid=2921312&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv74l637779268039%2F Conclusions  Concomitant radiotherapy–gemcitabine is active and well tolerated in newly diagnosed glioblastoma multiforme. Activity is observed both in tumors with methylated and unmethylated MGMT promoter. Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s00280-009-1155-xAuthors Giulio Metro, Regina Elena Cancer Institute Division of Medical Oncology Via Elio Chianesi, 53 00144 Rome ItalyAlessandra Fabi, Regina Elena Cancer Institute Division of Medical Oncology Via Elio Chianesi, 53 00144 Rome ItalyMaria A. Mirri, Regina Elena Cancer Institute Division of Radiotherapy Rome ItalyAntonello Vidiri, Regina Elena Cancer Institute Diagnostic Imaging Rome ItalyAndrea Pace, Regina Elena Cancer Institute Division of Neurology Rome ItalyMariantonia Carosi... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2921312 Wed, 21 Oct 2009 19:34:56 +0100 2921312 http://www.medworm.com/index.php?rid=2917459&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq2275184lw5q78j6%2F Conclusions  Platinum-based therapies are vital to the treatment of primary peritoneal and ovarian carcinoma. Protocols that successfully incorporate platinum agents, despite a platinum hypersensitivity, are clinically relevant. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1159-6Authors Daniel P. Greene, University of Virginia School of Medicine Charlottesville VA USAJames Stuart Ferriss, University of Virginia Health System Thornton Gynecologic Oncology Service, Department of Obstetrics and Gynecology P.O. Box 800712 Charlottesville VA 22908 USAAmir A. Jazaeri, University of Virginia Health System Thornton Gynecologic Oncology Service, Department of Obstetrics and Gynecology P.O. Box 800712 Charlottesville VA 22908 USA Journal Canc... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2917459 Wed, 21 Oct 2009 12:31:06 +0100 2917459 http://www.medworm.com/index.php?rid=2917460&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft7554g471506t374%2F Conclusions  The timing of clinical combination therapy doses is often selected empirically. PK/PD models provide a theoretical structure useful in the design of the optimal clinical dose, frequency of administration and the optimal timing of administration between anticancer agents to maximize tumor suppression. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1153-zAuthors Kosalaram Goteti, AstraZeneca R&D Boston Department of Drug Metabolism and Pharmacokinetics 35 Gatehouse Drive Waltham MA 02451 USAC. Edwin Garner, AstraZeneca R&D Boston Department of Drug Metabolism and Pharmacokinetics 35 Gatehouse Drive Waltham MA 02451 USALucas Utley, AstraZeneca R&D Boston Department of Drug Metabolism and Pharmacokinetics 35 Gatehouse Drive Waltham... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2917460 Tue, 20 Oct 2009 16:32:39 +0100 2917460 http://www.medworm.com/index.php?rid=2895740&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv92r188x7p673xt5%2F Conclusions  Although most patients had stage IV NPC, the TPF induction chemotherapy followed by CCRT showed promising activity with manageable toxicity. These results demonstrated the possibility of effective treatment with the aim of not only a palliative, but also a curative, approach to the treatment of advanced NPC. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1152-0Authors Woo Kyun Bae, Chonnam National University Medical School Department of Hematology-Oncology Gwangju 501-757 KoreaJun Eul Hwang, Chonnam National University Medical School Department of Hematology-Oncology Gwangju 501-757 KoreaHyun Jeong Shim, Chonnam National University Medical School Department of Hematology-Oncology Gwangju 501-757 KoreaSang Hee Cho, Chonnam Nati... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2895740 Wed, 14 Oct 2009 16:59:33 +0100 2895740 http://www.medworm.com/index.php?rid=2895739&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F56qmx6367h438q85%2F Conclusions  Since 5-FU + NSAID treatment can alter the DPD enzyme activity resulting in an enhanced cytotoxic effect, further studies in clinical practice are warranted. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1149-8Authors Andrea Réti, National Institute of Oncology Department of Clinical Research Budapest HungaryÉva Pap, National Institute of Oncology Department of Clinical Research Budapest HungaryVilmos Adleff, National Institute of Oncology Department of Clinical Research Budapest HungaryAndrás Jeney, Semmelweis University 1st Institute of Pathology and Experimental Cancer Research Budapest HungaryJudit Kralovánszky, National Institute of Oncology Department of Clinical Research Budapest HungaryBarna Budai, Nationa... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2895739 Wed, 14 Oct 2009 16:59:33 +0100 2895739 http://www.medworm.com/index.php?rid=2895741&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F4118102r66620342%2F Conclusion  These findings suggest that THTR2 down-regulation in breast tumors may present a nutritional vulnerability that could be exploited by thiaminase I enzyme therapy. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1148-9Authors Shuqian Liu, University of Kentucky College of Medicine Division of Pediatric Hematology-Oncology, Department of Pediatrics 740 S. Limestone Room J457 Lexington KY 40536 USANoel R. Monks, University of Kentucky College of Medicine Division of Pediatric Hematology-Oncology, Department of Pediatrics 740 S. Limestone Room J457 Lexington KY 40536 USAJeremiah W. Hanes, Cornell University Department of Chemistry and Chemical Biology Ithaca NY 14853 USATadhg P. Begley, Cornell University Department of Chemistry and C... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2895741 Wed, 14 Oct 2009 16:59:30 +0100 2895741 http://www.medworm.com/index.php?rid=2895742&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F06712304427u75k1%2F Conclusions  The results demonstrate that DIM-C-pPhC6H5 and indole ring-substituted analogs are selective PPARγ modulators. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1144-0Authors Jingjing Guo, Texas A&M University Health Science Center Institute of Biosciences and Technology Houston TX USASudhakar Chintharlapalli, Texas A&M University Health Science Center Institute of Biosciences and Technology Houston TX USASyng-ook Lee, Texas A&M University Health Science Center Institute of Biosciences and Technology Houston TX USASung Dae Cho, Chonbuk National University Department of Oral Pathology, Institute of Oral Sciences, School of Dentistry Jeonbuk South KoreaPing Lei, Texas A&M University Health Science Center Institute of Biosciences and ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2895742 Tue, 13 Oct 2009 08:15:31 +0100 2895742 http://www.medworm.com/index.php?rid=2883847&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw54251380k134157%2F Conclusions  Based on this retrospective analysis, the ovarian metastatectomy significantly prolonged survival in CRC patients with ovarian metastases. The potential role of an ovarian metastatectomy in the management of CRC should be prospectively studied. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1150-2Authors Su Jin Lee, Samsung Medical Center, Sungkyunkwan University School of Medicine Division of Hematology/Oncology, Department of Medicine 50 Ilwon-dong Kangnam-gu Seoul 135-710 KoreaJeeyun Lee, Samsung Medical Center, Sungkyunkwan University School of Medicine Division of Hematology/Oncology, Department of Medicine 50 Ilwon-dong Kangnam-gu Seoul 135-710 KoreaHo Yeong Lim, Samsung Medical Center, Sungkyunkwan University School of Me... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2883847 Sat, 10 Oct 2009 07:02:16 +0100 2883847 http://www.medworm.com/index.php?rid=2880502&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F4vr21t4423068275%2F Conclusions  This study revealed significant differences in the relative estimated PK parameters of the plasma, SC, peri-, and intratumoral zones. Additionally, this study demonstrated that the coadministration of MTX with CsA can enhance the intratumoral exposure levels of the drug, whereas coadministration of MTX with probenecid alone, or with a combination of probenecid and CsA, increases intratumoral half-life. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1146-yAuthors Shabnam N. Sani, Massachusetts College of Pharmacy and Health Sciences Department of Pharmaceutical Sciences 179 Longwood Avenue Boston MA 02115 USAKatherine Henry, Charles River Laboratories, In-Life Sciences, Preclinical Services 334 South St Shrewsbury MA 01545 USAM... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2880502 Fri, 09 Oct 2009 06:06:23 +0100 2880502 http://www.medworm.com/index.php?rid=2873311&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F82w78l75578223n0%2F Conclusion  This regimen is feasible in the treatment of patients with completely resected NSCLC. A multicenter phase III trial is warranted to assess the efficacy of this regimen at promoting survival and preventing recurrence. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1139-xAuthors Masafumi Yamaguchi, Respiratory Center and Clinical Institute, National Hospital Organization Kyushu Medical Center Division of General Thoracic Surgery Jigyouhama 1-8-1, Chuou-ku Fukuoka 810-8563 JapanSadanori Takeo, Respiratory Center and Clinical Institute, National Hospital Organization Kyushu Medical Center Division of General Thoracic Surgery Jigyouhama 1-8-1, Chuou-ku Fukuoka 810-8563 JapanRyuichi Suemitsu, Respiratory Center and Clinical Institute, ... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2873311 Wed, 07 Oct 2009 06:51:31 +0100 2873311 http://www.medworm.com/index.php?rid=2873312&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy8204437lk176281%2F Conclusions  Our in vitro results suggest that mRNA expressions of RanBP2 and TopoII isoforms are unlikely to be a predictive biomarker for the sensitivity to amrubicin. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1151-1Authors Yoshitsugu Horio, Aichi Cancer Center Hospital Department of Thoracic Oncology 1-1 Kanokoden, Chikusa-ku Nagoya 464-8681 JapanHirotaka Osada, Aichi Cancer Center Research Institute Division of Molecular Oncology 1-1 Kanokoden, Chikusa-ku Nagoya 464-8681 JapanJunichi Shimizu, Aichi Cancer Center Hospital Department of Thoracic Oncology 1-1 Kanokoden, Chikusa-ku Nagoya 464-8681 JapanShizu Ogawa, Aichi Cancer Center Hospital Department of Thoracic Oncology 1-1 Kanokoden, Chikusa-ku Nagoya 464-8681 JapanToyoaki Hida, A... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2873312 Wed, 07 Oct 2009 06:51:29 +0100 2873312 http://www.medworm.com/index.php?rid=2856506&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq7081g770478548t%2F Conclusions  Contrary to previous estimates for a UK population, genetic DPD deficiency accounts for around 19% of cases of severe fluoropyrimidine toxicity. The influence of DPD deficiency is such that toxicity can be avoided by prior testing and appropriate 5-FU dose/regimen alteration. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s00280-009-1147-xAuthors Aathavan Loganayagam, Guy’s and St Thomas’ Hospital NHS Foundation Trust Department of Gastroenterology 1st Floor, College House, St Thomas’ Hospital, Lambeth Palace Road London SE1 7EH UKMonica Arenas-Hernandez, Guy’s and St Thomas’ Hospital NHS Foundation Trust Purine Research Laboratory, GSTS Pathology 4th Floor, North Wing, St Thomas Hospital, Lambeth Palace Road London SE1 7EH U... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2856506 Wed, 30 Sep 2009 18:19:26 +0100 2856506 http://www.medworm.com/index.php?rid=2847961&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F78444466235740m1%2F Conclusions  Critical toxicity from NAD depleting cancer drugs to consider in future trials seems to be thrombocytopenia and various gastrointestinal symptoms. Efficacy of NAD depleting drugs when used alone is expected to be low. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1125-3Authors Anne von Heideman, Uppsala University Department of Oncology, Radiology and Clinical Immunology, Section of Oncology, University Hospital 751 85 Uppsala SwedenÅke Berglund, Uppsala University Department of Oncology, Radiology and Clinical Immunology, Section of Oncology, University Hospital 751 85 Uppsala SwedenRolf Larsson, Uppsala University Department of Medical Sciences, Section of Clinical Pharmacology, University Hospital 751 85 Uppsala SwedenPeter... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2847961 Tue, 29 Sep 2009 16:53:47 +0100 2847961 http://www.medworm.com/index.php?rid=2847962&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F20264j36560n446t%2F Conclusions  The PK of RAD001 differed between mice and rats, with rats having a PK profile closer to that of humans. High intermittent doses of RAD001 may be more appropriate for treatment of brain tumors. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1068-8Authors Terence O’Reilly, Novartis Institutes for BioMedical Research Department of Oncology Research WKL-125.13.17 4002 Basel SwitzerlandPaul M. J. McSheehy, Novartis Institutes for BioMedical Research Department of Oncology Research WKL-125.13.17 4002 Basel SwitzerlandR. Kawai, Novartis Pharma AG Department of Drug Metabolism and Pharmacokinetics Basel SwitzerlandO. Kretz, Novartis Pharma AG Department of Drug Metabolism and Pharmacokinetics Basel SwitzerlandL. McMahon, Novartis Ins... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2847962 Tue, 29 Sep 2009 04:04:48 +0100 2847962 http://www.medworm.com/index.php?rid=2847964&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq852431371036375%2F Conclusions  These factors should help determine the appropriate strategy for proposing a third line of chemotherapy. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1141-3Authors Elodie Vauléon, Comprehensive Cancer Center, E Marquis Department of Medical Oncology CS 44229 Avenue de la Bataille Flandres Dunquerke 35042 Rennes cedex FranceHabiba Mesbah, Comprehensive Cancer Center, E Marquis Department of Medical Information CS 44229 35042 Rennes cedex FranceBrigitte Laguerre, Comprehensive Cancer Center, E Marquis Department of Medical Oncology CS 44229 Avenue de la Bataille Flandres Dunquerke 35042 Rennes cedex FranceDaniel Gédouin, Comprehensive Cancer Center, E Marquis Department of Medical Oncology CS 44229 Avenue de la Bataille Flandre... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2847964 Tue, 29 Sep 2009 04:04:46 +0100 2847964 http://www.medworm.com/index.php?rid=2847963&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F92381768738625u6%2F Conclusion  These results add further evidence that purines present in normal culture conditions are important determinants of methotrexate cytotoxicity. Elevation of dATP levels after methotrexate treatment is an important modulator of cytotoxicity. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1142-2Authors Li Chong, The University of Sydney Department of Cancer Medicine, Blackburn Building D06 Sydney NSW 2006 AustraliaGuoyi Ma, The University of Sydney Department of Cancer Medicine, Blackburn Building D06 Sydney NSW 2006 AustraliaWendy A. Bartier, The University of Sydney Department of Cancer Medicine, Blackburn Building D06 Sydney NSW 2006 AustraliaMartin H. N. Tattersall, The University of Sydney Department of Cancer Medicine, Blackbur... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2847963 Tue, 29 Sep 2009 04:04:46 +0100 2847963 http://www.medworm.com/index.php?rid=2847965&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fymx6073g42733223%2F Conclusions  Aminopterin does not appear to offer any advantage over methotrexate for the treatment of childhood ALL. Further study of pemetrexed in childhood leukemias is warranted. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1120-8Authors Robin E. Norris, Abramson Research Center Division of Clinical Pharmacology and Therapeutics, Children’s Hospital of Philadelphia 3615 Civic Center Blvd., Suite 916 Philadelphia PA 19104 USAPeter C. Adamson, Children’s Hospital of Philadelphia Division of Oncology, Division of Clinical Pharmacology and Therapeutics Philadelphia PA USA Journal Cancer Chemotherapy and PharmacologyOnline ISSN 1432-0843Print ISSN 0344-5704 (Source: Cancer Chemotherapy and Pharmacology) Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2847965 Tue, 29 Sep 2009 04:04:45 +0100 2847965 http://www.medworm.com/index.php?rid=2835078&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe312h75jnt8n609u%2F Abstract  Multiple myeloma (MM) cells continuously secrete large amounts of immunoglobulins that are folded in the endoplasmic reticulum (ER) whose function depend on the Ca2+ concentration inside its lumen. Recently, it was shown that the ER membrane leaks Ca2+ that is captured and delivered back by mitochondria in order to prevent its loss. Thus, we hypothesized that the highly active and abundant ER in MM cells results in greater Ca2+-regulation by mitochondria which would render them sensitive to mitochondrial inhibitors. Here, we indeed find that Ca2+ leak is greater in 3 MM, when compared to 2 B-cell leukemia cell lines. Moreover, this greater leak in MM cells is associated with hypersensitivity to various mitochondrial inhibitors, including CCCP. Consistent with our hyp... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2835078 Thu, 24 Sep 2009 16:41:53 +0100 2835078 http://www.medworm.com/index.php?rid=2835079&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl32101n58666x1h5%2F Conclusion  Folate-targeting confers a significant albeit modest therapeutic improvement to PLD in FR-expressing tumor models, which appears particularly valuable in intracavitary therapy. The potential clinical added value of this approach has yet to be determined. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1132-4Authors Alberto Gabizon, Shaare Zedek Medical Center Experimental Oncology Laboratory 11 Shmuel Bayit Street, 7th Floor P.O. Box 3235 Jerusalem 91031 IsraelDina Tzemach, Shaare Zedek Medical Center Experimental Oncology Laboratory 11 Shmuel Bayit Street, 7th Floor P.O. Box 3235 Jerusalem 91031 IsraelJenny Gorin, Shaare Zedek Medical Center Experimental Oncology Laboratory 11 Shmuel Bayit Street, 7th Floor P.O. Box 3235 Jerusale... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2835079 Thu, 24 Sep 2009 16:41:51 +0100 2835079 http://www.medworm.com/index.php?rid=2835080&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F4075837437418721%2F Abstract  Retinoids are biologically active derivatives of vitamin A, which play essential roles in embryonic or adult cell behavior modulating cell proliferation, differentiation and apoptosis. The biologic effects of retinoids are mediated by two distinct families of intracellular receptors: retinoid acid receptors (RARs)-α, -β and -γ and retinoid X receptors (RXR)-α, -β and -γ. Bexarotene is a selective RXR agonist, which exerts its effects in blocking cell cycle progression, inducing apoptosis and differentiation, preventing multidrug resistance, and inhibiting angiogenesis and metastasis, making it a promising chemopreventive agent against cancer. Content Type Journal ArticleCategory Mini ReviewDOI 10.1007/s00280-009-1140-4Authors Liyan Qu, Zhejiang Universit... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2835080 Thu, 24 Sep 2009 05:47:20 +0100 2835080 http://www.medworm.com/index.php?rid=2833068&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx338818786gu1876%2F Conclusion  We conclude that SN 28049’s high tumour exposure and long tumour retention time is likely to contribute to its high antitumour activity in vivo. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1123-5Authors Pradeep B. Lukka, The University of Auckland Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences Private Bag 92019 Auckland New ZealandJames W. Paxton, The University of Auckland Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences Private Bag 92019 Auckland New ZealandPhilip Kestell, The University of Auckland Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences Private Bag 92019 Auckland New ZealandBruce C. Baguley, The University... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2833068 Wed, 23 Sep 2009 06:01:06 +0100 2833068 http://www.medworm.com/index.php?rid=2833070&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe17m37641432t021%2F Conclusion  Sequential paclitaxel and bortezomib in previously treated patients with advanced solid tumors resulted in acceptable toxicity and no evidence of interaction. The recommended phase II dose of bortezomib in combination with weekly paclitaxel was 1.8 mg/m2. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1145-zAuthors Bhuvaneswari Ramaswamy, The Ohio State University B401, Starling Loving Hall, 320 W 10th av Columbus OH 43210 USATanios Bekaii-Saab, The Ohio State University B401, Starling Loving Hall, 320 W 10th av Columbus OH 43210 USALarry J. Schaaf, The Ohio State University B401, Starling Loving Hall, 320 W 10th av Columbus OH 43210 USAGregory B. Lesinski, The Ohio State University B401, Starling Loving Hall, 320 W 10th... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2833070 Wed, 23 Sep 2009 06:01:05 +0100 2833070 http://www.medworm.com/index.php?rid=2825702&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F62x592184895mv23%2F Conclusions  The combination had moderate, but manageable toxicity. In the future studies, lower dose for capecitabine is recommended. The combination was active and the response rates seen here were in line with phase-II studies on former combinations of non-pegylated interferons. One complete remission was achieved. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1134-2Authors Kaisa Leea Sunela, Tampere University Hospital Department of Oncology P.O. Box 2000 33521 Tampere FinlandSanna Koskinen, University of Tampere Medical School, University of Tampere Department of Oncology 33014 Tampere FinlandPirkko-Liisa Kellokumpu-Lehtinen, Tampere University Hospital Department of Oncology P.O. Box 2000 33521 Tampere Finland Journal Cancer C... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2825702 Mon, 21 Sep 2009 16:03:40 +0100 2825702 http://www.medworm.com/index.php?rid=2825701&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe7553107827818nw%2F Conclusions  Together, these results show that blockage of AT1 receptor signaling may be a promising anti-tumor strategy, interfering with angiogenesis by decreasing the expression of angiogenic factor receptors. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1136-0Authors Andréia Hanada Otake, Faculdade de Medicina da Universidade de São Paulo Laboratório de Oncologia Experimental (LIM-24), Departamento de Radiologia e Instituto do Câncer do Estado de São Paulo Av. Dr. Arnaldo, 455 room 4112/4122 São Paulo SP 01246-903 BrazilAna Lucia Mattar, Departamento de Clínica Médica da Faculdade de Medicina da Universidade de São Paulo Laboratório de Fisiopatologia Renal (LIM-16) São Paulo BrazilHelano Carioca Freitas, Faculdade de Medicin... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2825701 Mon, 21 Sep 2009 16:03:40 +0100 2825701 http://www.medworm.com/index.php?rid=2825700&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn31146h6q28l7730%2F Conclusions  The ex vivo chemoresponse of EC and SC of HNSCC must be analyzed separately. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1124-4Authors Iris-Susanne Horn, University Hospital Leipzig Department of Otorhinolaryngology, Head and Neck Surgery Liebigstraße 10-14 04103 Leipzig GermanyGunnar Wichmann, University Hospital Leipzig Department of Otorhinolaryngology, Head and Neck Surgery Liebigstraße 10-14 04103 Leipzig GermanyChristian Mozet, University Hospital Leipzig Department of Otorhinolaryngology, Head and Neck Surgery Liebigstraße 10-14 04103 Leipzig GermanyAndreas Dietz, University Hospital Leipzig Department of Otorhinolaryngology, Head and Neck Surgery Liebigstraße 10-14 04103 Leipzig GermanyRalph Dollner, University Hos... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2825700 Mon, 21 Sep 2009 16:03:40 +0100 2825700 http://www.medworm.com/index.php?rid=2825704&cid=s_33439_6_f&fid=33439&url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl732138778030849%2F Conclusions  The cytotoxic effect of gef gene in breast cancer cells enhances the chemotherapeutic effect of doxorubicin. This therapeutic approach has the potential to overcome some of the major limitations of conventional chemotherapy, and may therefore constitute a promising strategy for future applications in breast cancer therapy. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1135-1Authors Jose Prados, University of Granada Department of Human Anatomy and Embryology, School of Medicine, Institute of Biopathology and Regenerative Medicine (IBIMER) 18071 Granada SpainConsolación Melguizo, University of Granada Department of Human Anatomy and Embryology, School of Medicine, Institute of Biopathology and Regenerative Medicine (IBIMER) 18... Cancer Chemotherapy and Pharmacology journals http://www.medworm.com/rss/comments.php?id=2825704 Mon, 21 Sep 2009 16:03:36 +0100 2825704